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Biological membranes deﬁne the boundaries of cells and
compartmentalize the chemical and physical processes
required for life. Many biological processes are carried out by
proteins embedded in or associated with such membranes.
Determination of membrane protein (MP) structures at atomic
or near-atomic resolution plays a vital role in elucidating their
structural and functional impact in biology. This endeavor has
determined 1198 unique MP structures as of early 2021. The
value of these structures is expanded greatly by deposition of
their three-dimensional (3D) coordinates into the Protein Data
Bank (PDB) after the ﬁrst atomic MP structure was elucidated
in 1985. Since then, free access to MP structures facilitates
broader and deeper understanding of MPs, which provides
crucial new insights into their biological functions. Here we
highlight the structural and functional biology of representative MPs and landmarks in the evolution of new technologies,
with insights into key developments inﬂuenced by the PDB in
magnifying their impact.

As membranes were critical to the separation of chemistries
essential to the origin of life, membrane proteins (MPs) are key
players in some of the most important physiological processes
in living organisms. Characterizing MPs structurally and
functionally is still extremely challenging due to their frequent
low abundance, and difﬁculties in purifying functional MPs
intact from their native membrane, though it is going through
an exciting revolution now due to several key factors. It took
several decades to obtain the structural information that now
allows pursuit of understanding MP function in health and
disease, to manipulate them as drug targets, and to engineer
them into new powerful tools to fuel discovery. We highlight
some of the landmarks in this endeavor that drove or
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depended on the discovery of new technologies required speciﬁcally for structural studies of membrane, versus soluble
proteins.
Previously, hand-written letters delivered by post requested
coordinate sets that were not always readily given. The vision
of Hamilton, Myer, Koetzle, and the joint venture between the
Cambridge Crystallographic Data Center in the United
Kingdom and the Brookhaven National Laboratories at Stony
Brook University led to the Protein Data Bank (PDB). Then for
the ﬁrst time, one could begin to ask questions with all the
relevant structures at hand. In celebrating 50 years of the PDB,
we focus on some of the ingeniously crafted inventions and
discoveries that led the way for entire classes of MPs, and those
new approaches that now promise structures of large and
complex machines from their native cellular environments, in
action.
In the following Historical perspective, we provide a brief
historical perspective of some MP insights (other than the
crucial G-protein-coupled receptors (GPCRs) that are the
subject of a dedicated review in this volume) and consider the
value of the PDB in disseminating this information. Seemingly
insurmountable difﬁculties were often overcome with invention of new technologies to reveal important structural features of classes of MPs that make the fabric of today’s
approaches.
In How do membrane proteins accomplish key physiological
functions?, we describe how the structures of several of the
major MP classes were uncovered, which often required
technological developments that are now woven into the fabric
of structural biology. First, how are the α-helical, tail-anchored,
and all β-sheet MP broad categories correctly targeted to and
inserted into membranes and allowed to fold correctly? We
progress to landmark discoveries involving the roles of MPs in
physiology and some of the critical barriers that had to be
overcome to realize these achievements. How do water channels conduct water at diffusion limited rates without allowing
leakage of protons (H+) or hydronium ions (H3O+) or any
other ions? How do potassium channels conduct K+ ions, but
J. Biol. Chem. (2021) 296 100557

1

© 2021 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).

JBC REVIEWS: Membrane proteins: Celebrating 50 years of the PDB

Robert M. Stroud, Professor of Biochemistry and Biophysics, University of California
San Francisco, has contributed fundamental
insights into how signals are propagated
across membranes by his work on the
structures of membrane proteins and proteins associated with membrane-localized
processes.

not the Na+ ion of similar charge and smaller ionic radius?
How are epithelial cells held together side by side to make a
selectively permeable sealed layer of cells? The question of how
substrates are transported across membranes using energy
then follows. How does one superfamily of “primary” transporters, the “ABC transporters” that directly harness ATP
hydrolysis on their cytoplasmic side, move materials across
membranes? How does another superfamily of “secondary”
transporters, the Major Facilitator Superfamily (MFS), use ion
or proton electrochemical gradients to drive nutrient import,
export, or efﬂux of xenobiotics? We progress to consider a
specialized class of essential viral proteins that form channels
that are essential for viral virulence.
In Membrane protein structures instruct drug design and
protein engineering, we focus on a few examples of therapeutics and opportunities for engineering of MPs. Critical to any
therapeutic drugs are the membrane-attached cytochrome
P450s that are discussed in the light of their key roles in sterol
metabolism, but as metabolizers of therapeutic drugs, and
therefore as drug targets themselves. Structures help elucidate
mechanisms of action of therapeutics to modulate MP activities. The Cystic Fibrosis Transmembrane-Conductance
Regulator (CFTR) is used as an example of the impact structural studies can have on the understanding and treatment of
rare diseases. Another example addresses glucose import as an
anticancer target opportunity. A key example in neurology is
the class of ligand-gated ion channels, represented by GABAA
receptors (GABAAR) and their ligands. Then the Leucine
Transporter (LeuT), representing several classes of transporters with a common core of ten trans-membrane α-helices
(TMs), is used to illustrate how major antidepressants work.
Finally, some exciting developments in MP engineering focus
on channelrhodopsins where light can trigger cellular responses and engineered dopamine sensors.
We hope that this necessarily limited perspective on the
impact of selected MP structure classes may encourage opportunities in a broader context. We hope to communicate the
value of MPs as guardians of the health of cells and how their
structures, through the PDB, contribute important insights
into many crucial aspects of physiology.

Historical perspective
A brief history of membrane protein structures and the PDB
With soluble proteins beginning with myoglobin in 1961,
followed by lysozyme, hemoglobin, and digestive proteases,
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these were available only from large animals or from bacteria.
Long before overexpression systems became available, the
number of soluble macromolecular structures followed an
exponential growth. This pattern was noted by Dickerson in a
letter written to the PDB in 1978 (1). The ﬁrst integral MP
structure was not determined until 25 years later in 1985. The
number of MP structures determined and deposited in the
PDB since that time also increased exponentially, but with a
smaller exponent reﬂecting the considerable challenges that
pertain to MP structural biology. The amount of time for the
number of unique MP structures to double was about 3 years
compared with 2.4 years for soluble macromolecules (2). This
doubling time for MPs slowed to 5 years recently (Fig. 1).
Most obvious challenges are functional expression in a limited
lipid membrane environment versus expression in a soluble
volume, followed by the requirement for detergents, amphiphiles, and lipids during extraction and puriﬁcation of functional proteins from the membrane. There were critical
breakthroughs necessary for many new classes of MPs over the
last three decades. As a reﬂection, on January 15th, 2021, there
were a total of 4569 coordinate ﬁles for MPs in the PDB, barely
2.6% of the total for all proteins, and of these 1203 represent
unique structures. This is brilliantly tracked and annotated by
Stephen H. White’s invaluable mpstruct database of MPs of
known structure (Fig. 1) (2) (https://blanco.biomol.uci.edu/
mpstruc/), and by statistical and thermodynamic analyses
from Thomas Newport, Mark Sansom, and Phillip Stansﬁeld
in their MemProtMD database (3). One of our aims here is to
celebrate some of these developments in association with the
breakthroughs by those that made them possible.
Like those in the 1960s who worked on the soluble proteins
available in quantity from the tissues of large animals or bacteria, work on the ﬁrst MP structures also focused on rich
natural sources. The purple membrane of archaebacteria was
ﬁrst described in 1971 by Oesterhelt and Stoeckenius, who
showed that it contained a light-driven proton pump. This
validated the Mitchell hypothesis, the revolutionary concept
that biological energy could be stored as a proton gradient
across a membrane (4, 5). By freeze-fracture electron microscopy, they showed that “bacteriorhodopsin” formed an inplane trigonal two-dimensional (2D) lattice. This was pursued structurally by Henderson and Unwin using electron
diffraction of the arrays formed in the membrane (6), by
Michel working with Oesterhelt, who attempted to crystallize
the protein using detergents (7–10), and by Blaurock using Xray scattering to demonstrate that α-helices were oriented
perpendicular to the membrane plane (11, 12). Henderson and
Unwin produced the ﬁrst electron diffraction patterns from
the trigonal latticed membranes, puriﬁed from the natural
source, by sustaining its single bilayer in a glucose solution to
prevent dehydration in the electron microscope (6). In a
towering landmark, in 1975, they phased the patterns based on
the images and reconstructed a 7 Å resolution 3D structure
that beautifully demonstrated that the protein is comprised of
seven TMs (6). This ﬁrst discovery using electron microscopy/
diffraction was at the heart of the concepts later recognized by
the Nobel prize in chemistry to Henderson, Frank, and
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Figure 1. Timeline depicting the progress in structural biology since the PDB was established in 1971 and evolution of membrane protein
structural biology since 1985. The curve showing the cumulative total of unique MP structures deposited in the PDB (mostly by X-ray crystallography and
cryo-EM) as a function of time is adapted from the mpstruct website of Stephen White at the University of California, Irvine at https://blanco.biomol.uci.edu/
mpstruc/. The red curve models the expected exponential growth at year 20 (2005). Dates corresponding to key scientiﬁc or technical discoveries that
fostered breakthroughs in deciphering and understanding (membrane) protein structure and function are indicated. Some of the ﬁrst protein structures
reported for important classes are indicated along the timeline. Many of the ﬁrst MP structures were solved in detergent but later in lipidic cubic phase
bilayers LCP, bicelles, amphipols, and nanodiscs. ED: electron diffraction. DED: direct electron-counting detector. Rfree: test set cross-validation for crystallographic reﬁnement. FSC: Fourier shell correlation for cryo-EM single-particle reconstruction validation. LH: light harvesting complex. Chloroquine DMT:
chloroquine-resistance drug/metabolite transporter. This list does not pretend to be exhaustive. The Protein Structure Initiative from the National Institute of
Health in the United States spanned the years 2000 to 2015 (shaded in light green). Nobel prizes awarded for discoveries related to MP biology and structure
are indicated. The central motivation behind the “Molecule of the Month” (35 MPs since its creation) is to provide a user-friendly introduction to a rich body
of data, providing users with a path to get started with ﬁnding and exploring the many available structures and thus offering a resource for molecular
biology educators and students around the world at http://pdb101.rcsb.org (81).

Dubochet in 2017. Soon after, in 1977 to 1979, the amino acid
sequence of bacteriorhodopsin was determined by the groups
of Khorana (13) and Ovchinikov (14, 15) using chemical
sequencing methods. Agard and Stroud developed computational ways to extend resolution perpendicular to the membrane plane in attempts to reveal the interhelix linker regions
to map sequence into the structure from electron diffraction
data (16). With Glaeser, who pioneered low-temperature
electron microscopy (17, 18), Hayward and Stroud developed
a way of aligning microcrystalline regions to extend resolution
of the reconstructions to 3.8 Å in-plane resolution (19). As a
reﬂection of the extreme challenges for membrane versus
soluble proteins, the bacteriorhodopsin structure reached
atomic resolution by electron diffraction 20 years after the

1975 breakthrough in 1996 (20, 21) and by X-ray diffraction in
1997 (22) (Fig. 1).
The cytochrome oxidase from bovine tissues (23, 24) and
the acetylcholine receptor from electric rays and eels (25–29),
respectively, key to oxidative phosphorylation in mitochondria
(see Early breakthroughs in High Resolution Structures of
Bioenergetic Membrane Complexes and Lipid Interactions)
and function of the neuromuscular junction, also provided
highly important sources of MP complexes. Beginning in 1971,
the ﬁrst 3D surface shapes of the acetylcholine receptor
300 kDa complex of ﬁve homologous subunits in a quasiﬁvefold pentameric complex αβαγδ were revealed using lowdose negative stain EM and small-angle X-ray scattering
from stacked membranes by Stroud and Unwin (30–35). The
J. Biol. Chem. (2021) 296 100557
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primary sequence, determined initially by Michael Raftery
using amino acid sequencing for 50 amino acids of each of the
four homologous subunits (28, 36), and in parallel by JeanPierre Changeux for the α-chain N-terminal sequence (27,
29), led to the cloning and sequencing of the genes (37). It
became clear that like bacteriorhodopsin, it too contained
TMs. The right-handed α-helix ﬁrst delineated by Pauling (38)
provided the necessary shielding of all polar groups, namely
the carbonyls and amides of the polypeptide backbone. Hence,
a sequence of 19 hydrophobic amino acids became a
recognizable signal for TMs, while strongly amphipathic helices signal membrane surface-seeking helices (39). Remarkable insights followed from the few MP structures already
determined, including the ﬁnding that their hydrophobic helices formed well-ordered 3D structures in lipid bilayer
membranes and their retention even after gentle extraction in
amphiphiles and detergents. Yet it took 45 years to obtain the
ﬁrst atomic structures for the acetylcholine receptor. This
required screening of many speciﬁc genetic constructs of
several members of this receptor family (40, 41).
The ﬁrst atomic resolution structure of any integral MP
came from the group of Michel in 1985 (42). After many years
trying to crystallize bacteriorhodopsin, Michel and Oesterhelt
had appreciated the value of colored proteins such as bacteriorhodopsin. Visible bands on columns aided puriﬁcation, and
more importantly, where the color of unique spectral features
reﬂected the integrity of the MP (43) and signaled for monitoring structural preservation in harsh solubilizing detergents.
Using photobacteria as a rich source of photosynthetic proteins, Michel and colleagues determined the ﬁrst MP structure
from crystals that diffracted to atomic resolution (3 Å and then
at 2.3 Å). The structure of the Rhodopseudomonas viridis
photosynthetic reaction center of 145 kDa published in 1984
(42) remains an amazing achievement. It showed that the
predominantly hydrophobic α-helices are often longer than
enough to span the 40 Å bilayer and can be correspondingly
tilted at different angles to harbor the many chromophores
that harness the light that supports life. This breakthrough
discovery was recognized by the Nobel prize in chemistry in
1988 to Michel, Deisenhofer, and Huber (Fig. 1).
Ion channels in membranes were in the limelight because
they accounted for the currents across membranes that are key
to the nervous system, as described by Hodgkin, Huxley, and
Katz in 1952 (44–46), and beautifully elaborated since then.
The key was that Na+ ions are consistently pumped out of the
mammalian cell using energy from ATP hydrolysis, while potassium ions remain inside to balance the electrochemical potential across the plasma membranes according to the Nernst
equation. In neurons, however, the need for fast communication relies on rapid conduction of the Na+ ions inward that is
signaled by the release of neurotransmitters at neuronal synapses that depolarize the plasma membranes of the target cell.
This is then rapidly followed by release of K+ ions though highly
selective channels that do not leak the smaller Na+ ions, but
restore the transmembrane electrical potential. How is such
selectivity accomplished? The alkali metal Na+ and K+ ions
differ in ionic radius, yet why don’t K+ channels leak the smaller

4 J. Biol. Chem. (2021) 296 100557

Na+ ion? The answer came in MacKinnon’s ﬁnding that bacterial K+ channels existed and could be extracted for structure
determination. In 1998, he reported the ﬁrst K+ channel
structure (KcsA) from the bacterium Streptomyces lividans
(47). The structure showed precisely how its selectivity was
achieved. The key was in the precise arrangement of a fourfold
arrangement of lines of carbonyl oxygens that surround a
“selectivity ﬁlter” (SF) in the pore entry. They provide the
precise counterpart for the normal water hydration shell
around the K+ ion, but were too far apart to provide similar
energy balance for the Na+ ion. MacKinnon was awarded the
Nobel Prize in chemistry for this landmark discovery in 2003
(Fig. 1).
The 2003 Nobel prize in chemistry was shared with Agre,
recognizing another remarkable discovery, that of water
channels (48). In 1985, Benga et al. (49, 50) demonstrated that
red blood cells had water channels that were inhibitable by
mercurials, implying that a sulfhydryl containing protein was
responsible. They showed that this was true across many (now
all) species, and Nielsen and Agre (51) showed that water
channels presented in all cells but for various physiological
purposes. They showed that there were 13 different variants in
human tissues and named them Aquaporins (AQPs) (52).
These were more difﬁcult to recognize than ion channels
because there were no electrical properties to measure their
activity. Their discovery was made while searching for the wellknown rhesus (Rh) factors in red blood cells. They discovered a
second major MP in these cells, and then showed that it conducted water, and at a speed up to the diffusion-limited values
for a pore of the requisite size (see below). Structures of the
aquaporins were determined in 2000 by electron imaging (53)
and at atomic resolution by X-ray crystallography (54), showing
precisely how these channels excluded passage of protons (H+)
or hydronium ions (H3O+), while allowing a single ﬁle of water
molecules to progress, hydrogen bonded to themselves, and to
eight key carbonyl oxygen atoms that act like pitons along the
walls of the channel (55).
An outstanding landmark was the structure of the F1FoATPase by Walker in 1994 (56) and its dynamo-like rotation
that harnessed proton gradients to drive the synthesis of ATP
in mitochondria. These critical structures of a 500 kDa
complex provided the amazing link to elucidate the subunit
stoichiometry of eight different protein chain types needed to
harness proton gradients to produce ATP, the major source of
energy in all cells. The discoveries led to the Nobel Prizes in
chemistry in 1997 to Boyer and to Walker, who reported the
atomic structure of the complex in 1994 (56) (Fig. 1).
The LeuT structure determined by Gouaux’s group signaled
a new approach to several related transporters that are critical
to mental health, responses to neurotransmitters, to therapeutic and street drugs (57–60). This ﬁrst structure provided a
landmark insight into the transporters that are required to
repackaged and reabsorb neurotransmitters back into the
neuronal cell after release into neurological synapses. Dopamine, serotonin transporters, and others from the same family
are all targets of therapies for the critically important spectrum
of neurological disorders (61). These transporters are also key
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to the control of major mental diseases including such poorly
understood disorders as schizophrenia and bipolar disease that
together affect 1/50 persons globally. The PDB now provides
a critical catalyst for disciplines that need to “know what we
are dealing with” in human health versus disease. It creates a
scenario in which we can think about and design strategies for
modulating therapeutic responses as well as providing an
ongoing reminder of how evolution has separated chemistries
in order to provide the essence of life.
With increasing impact on prospects for drug discovery,
structures of membrane embedded proteases that cleave
transmembrane regions to release components are critical.
One of the ﬁrst key examples was discovered by Brown,
Goldstein, and colleagues in the critical regulation of cholesterol metabolism. In recognition of their many contributions
to the broader ﬁeld of cholesterol metabolism, they were
awarded the Nobel prize in Physiology and Medicine in 1985.
They subsequently showed that a membrane-embedded S1P
serine protease cleaves the sterol regulatory element-binding
protein SREBP. A second intramembrane protease S2P, a
zinc metalloprotease, liberates a transcription factor from the
N terminus of SREBP that then upregulates cholesterol synthesis. These proteases also coordinate fatty acid synthesis that
is also required for membrane biogenesis (62–64). Rhomboid
proteases constitute another superfamily of ubiquitous intramembrane proteases involved in a wide range of biological
processes and were the ﬁrst structures of intramembrane
proteases to be determined (65). Another critical example of
intramembrane proteolysis is the cleavage of the β-amyloid
precursor protein (APP) by the β-site cleaving enzyme
(BACE1) that converts APP to the pathogenic forms Aβ42/40.
Validated by mouse gene knockouts, BACE1 and related γsecretase (66–68) are thus targets for drugs (69, 70). In spite of
extremely difﬁcult clinical trials, these targets remain as
promising modulators of Alzheimer’s disease (71). Many of the
intramembrane proteases destabilize the α-helical regions that
characterize transmembrane proteins and often don’t rely on
speciﬁc amino acid side chains for speciﬁcity as do the soluble
proteases.
As a portent of the impact of electron microscopy, the
discovery of the TRPV1 channel structure came after several
groups had puriﬁed and tried extensively to crystallize
Transient Receptor Potential (TRP) channels for many years
in seeking the structural basis for their roles in pain sensing
(72). As cryo-EM technologies improved, driven by single
electron counting “direct detectors” for cryo-EM (73), TRPV1
ﬁnally became tractable. This breakthrough by Cheng
working with Julius heralded the maturation of cryo-EM
applied to MPs (72, 74). It was harnessed by structural biologists particularly with integral MPs where the challenges
of crystallography and pressure for discovery were already
high (75–80) (Fig. 1).
As a critical library of the molecular bases for MP function,
the PDB provides a historical timestamp of the progression in
our understanding of these important proteins. It uniquely
affords a quantitative visual imprint of the mechanisms of
these proteins as the gatekeepers, importers, and exporters of

the cell and of organelles within the cell, to the beneﬁt of
current and future generations.
Early breakthroughs in high-resolution structures of
bioenergetic membrane complexes and lipid interactions
The story of MP structure determination and its profound
impact on understanding biological systems is a fascinating
illustration of the power of technology development and the
value of rapid communication of detailed structural information through the PDB. The problem of transferring MPs from
lipid environments to an aqueous phase is substantial and was
perhaps initially underestimated due to the prevalent concept
that the detergents needed to accomplish this feat were
intrinsically disordered and simply required to create a notnecessarily-homogeneous hydrophobic phase to cover newly
exposed membrane-embedded regions. Indeed, the importance of pure, well-deﬁned detergents was not immediately
recognized, and when it was, the chemistry for creating and
purifying these amphipathic compounds was challenging. But
gradually it became clear that achieving high-resolution MP
crystal structures required a protein sample that had not only
native activity and a high degree of purity but also was
dependent on the speciﬁc structure and purity of the detergent
itself for achieving these ends. In many cases, success also
depended on retaining a subset of structurally important lipids
(82).
Following the advent of the earliest high-resolution MP
structure (42), the importance of speciﬁc lipid interactions
became increasingly apparent: the lipidic detergent molecules
as well as native lipids were not just satisfying the need for a
disordered hydrophobic phase, but many were actually ﬁtting
into deﬁned, conserved slots in the protein structure. The
most dramatic illustrations of this fact came initially from the
complexes of the electron transport chain. One of the ﬁrst of
these to be obtained at high resolution was the structure of
mammalian cytochrome c oxidase, also known as Complex IV
(83), in which many lipids were resolved, with up to 13 bound
to each monomer of 200 kDa molecular weight. These lipids,
characterized by mass spectrometry, were found to be speciﬁc
not only in their placement, occupying the same positions in
each preparation, but also in head group and tail length and
degree of saturation (82) (Fig. 2). Many of the same lipidbinding sites were also found to be conserved in structures
of bacterial cytochrome c oxidase (84–87). In the bacterial
enzyme structure, several of the lipid grooves were occupied by
detergent (84), demonstrating that the lipid/detergent-binding
sites play important and speciﬁc roles in the native protein
structure. Similar results were found in crystal structures of
mammalian and yeast cytochrome bc1 (Complex III of the
electron transport chain) (88–90) and the plant homolog, cytochrome b6f (91, 92). The retention of resolved lipids in
conserved positions emphasizes the importance of lipid and
detergent structure in the maintenance of the native state.
As a variety of new, pure, chemically deﬁned detergents
became available (93, 94), including the successful sugar-based
decyl and dodecyl maltosides (95, 96) and many more designs
(94, 97), the ﬁeld moved rapidly forward despite the
J. Biol. Chem. (2021) 296 100557
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Figure 2. Bovine cytochrome c oxidase (Complex IV) monomer with
speciﬁcally bound lipid. The 13-subunit monomer structure (PDB 2EIL
chains N–Z) is shown, with associated lipids in dark red, buried hemes in
dark gray, and membrane region delineated by lipid placement. Subunits: I,
cornﬂower blue; II, sienna; III, blue; IV, navy; Va, purple; Vb, light green; VIa,
green, VIb, olive, VIc, forest green; VIIa, yellow; VIIb, gold; VIIc, orange; VIII,
khaki.

challenging fact that proteins buried in membranes often have
ﬂexible conformations required for their complex roles as receptors and transporters (98, 99). Although achieving very
high-resolution structures (<2 Å) remains difﬁcult, high resolution is essential where function involves conformational
change or depends on the positioning of water. Again, the
large multisubunit complexes of the mitochondrial electron
transport chain have provided insightful success stories, in part
due to their distinct spectral characteristics that aided puriﬁcation of native forms. These membrane-embedded, spectrally
unique proteins were among the ﬁrst to be structurally deﬁned
at high resolution, after the groundbreaking achievement of
the bacterial reaction center by Deisenhofer et al. (42), and
helped move the ﬁeld of bioenergetics into a new era of
mechanistic understanding. The structures of these large
complex proteins revealed the exact positioning of their many
prosthetic groups, enabled the subunit composition to be
conﬁrmed, and allowed meaningful interpretation of spectral
changes and fast kinetic analyses of electron transfer events.
Their unique UV–visible characteristics were powerful tools
for assessing the native state of the puriﬁed proteins and for
analyzing the rates and ordering of electron and proton
transfer events. Without structures that showed water positions and sometimes distinct hydrogen-bonded water chains
(84, 100), their kinetics could not be deﬁnitively interpreted.
High-resolution structures led to the clariﬁcation of the proton
transfer process, by the Grotthus mechanism, ﬁrst suggested in
1806 by Theodor von Grotthuss (101, 102) and brought us to
our current understanding of how coupling of electron
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transfer, oxygen reduction, and proton transfer leads to energy
conservation in most living organisms. But the supreme success story from the bioenergetics ﬁeld was capturing the machinery that completes the energy transducing process, the
ATP synthase (56) whose structure enabled the deciphering of
how rotational motion could be driven by the proton motive
force to generate ATP. Beautiful structures of this amazing
machine from the Walker group and others, initially without
its membrane-embedded region but still the largest asymmetric protein structure known at the time, continue to reveal
new and surprising aspects of how energy is transduced (103–
105).
With the understanding of the importance of speciﬁc lipid
interactions came increased efforts to create more lipidmimetic detergents (97) and to devise methods of retaining
native lipids and lipid-like molecules in the puriﬁed MPs. One
of the successful approaches was creating a lipidic “cubic
phase” (LCP) or meso-phase (22, 106, 107) that involved
mixing a speciﬁc ratio of lipid (such as monoolein) and
aqueous phase to form a membranous lipid organization into
which the protein could insert, maintaining a membrane-like
environment. Otherwise difﬁcult-to-crystallize proteins are
able to diffuse and form well-diffracting crystals in this phase,
with many success stories (107–109) including bacteriorhodopsin, the thermophilic covalent cytochrome c-cytochrome c
oxidase complex (110), and many GPCRs (111) (see review by
Stevens et al. in this issue).
Another important achievement stimulated by the need for
speciﬁc lipid interactions was the design of bicelles and
nanodiscs (112, 113) and surrogates to membrane lipids such
as amphipols (114, 115). Nanodiscs were created by encircling
a small portion of lipid and a captured MP using scaffold
proteins derived from apolipoproteins (113) or with chemical
polymers such as styrene-maleic acid (116). Bicelles are similar
but are self-assembling small model membrane systems edged
by bile salt lipids. Bicelles were initially designed to aid in
aligning MPs in a magnetic ﬁeld suitable for NMR analysis
(112). Nanodiscs, with added stability and control of size, have
been useful for many types of analysis including singlemolecule studies, activity studies, and resolving aggregation
state issues, as well as facilitating the use of cryo-EM. This
latter major technical development has further enabled MP
structure determination, with the use of single-particle cryoEM and the nanodisc method showing great success (117).
A revolution in cryo-EM detector methodology and
computational analysis has facilitated new levels of resolution
of very large complexes in different conformations even in a
single sample (Fig. 1). Again, the electron transfer chain has
been the subject of dramatic early success stories, with the
most impressive being complex I (118–120), the largest respiratory chain component with 45 subunits. These structures
also show speciﬁcally bound lipids and reveal the likely proton
routes through the membrane segment. Having the Complex I
structure was essential, in turn, to solve the atomic resolution
structures of supercomplexes up to 1.7 MDa.
The story of supercomplexes of the electron transport chain
is a long and controversial one (121–124). It required the new
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high-resolution cryo-EM technology to ﬁnally convincingly
establish their existence. But their functional signiﬁcance remains much debated (125–127). One key to successfully
deﬁning the atomic resolution structures of these unusually
large assemblies has been the availability of X-ray structures of
all the components, along with sophisticated computational
ﬁtting methods. A number of different assemblies have been
discovered (117, 121), some with Complexes I-IIIx2-IV, others
with two of complex IVs (but not associated as a dimer). A
recent version of the human supercomplex denoted the
megacomplex (128), which shows an assembled dimer of two
supercomplexes and suggests a place into which Complex II,
the only missing member of the chain, would ﬁt. The
continuing issue of the functional signiﬁcance of these assemblies remains. The question of what is the true native
assembled state and how dynamic it is contributes to this issue
(129). A recent ﬁnding is that the cytochrome c oxidase
(Complex IV) monomer form appears to be signiﬁcantly more
active than the dimer (130, 131). Since Complex IV appears as
a monomer in all the supercomplexes so far established, this
may be revealing an important new regulatory mechanism.
These amazing structures of the respiratory machinery have
led the way in illuminating not only unique protein structures
and functions, but also the fundamental role of lipid in MP
integrity. Their accessibility through the PDB in the most
useful formats continues to allow us to test hypotheses and to
excite our imagination, stimulating new modeling efforts and
new concepts in the ﬁeld of bioenergetics and pushing the
boundaries of our understanding of energy metabolism in
health and disease. These early results provided the initial
demonstration that it was possible to obtain crystal structures
of MPs of even massive dimensions and expanded our understanding of lipid environments that were needed to permit
this achievement.

How do membrane proteins accomplish key
physiological functions?
Residing in the boundaries of cells and their organelles, MPs
and their complexes underpin many important aspects of cell
physiology that can be addressed through structures held in
the PDB. A representative repertoire of these physiological
functions includes how MPs are correctly chaperoned and
inserted into their correct host membrane, how some proteins
are secreted across membranes. How is osmotic balance
maintained by water channels that do not leak any protons or
ions, and how ions are speciﬁcally passaged by gated channels?
How are cells held together in surfaces of the skin and organs
with appropriate paracellular transport? The bioenergetic
transformations required for ATP synthesis (respiratory electron transfer complexes, ATP synthases), maintenance of
membrane potential (P-type ATPases), production and control
of ion gradients (ion channels), sequestration and export of key
regulators such as calcium ions (sarcoplasmic reticulum and
plasma membrane calcium ATPases), transport of nutrient,
toxin and xenobiotic through primary active transporters
driven by ATP hydrolysis (ABC transporters) and secondary
active transporters driven by proton plus electrochemical

gradients. We summarize the MFS transporters and also
describe viroporins (VPs), small viral MPs that form channels
necessary for virulence. These structures offer routes to drug
discovery that are often broader than simply inhibition, such as
modulation or even enhancement of activities. While the examples we have chosen illuminate the value of the PDB in
providing structure–function insight into basic biological
phenomena and their possible application, our goal is to
provide an instructive vision rather than a comprehensive
oversight.
How are membrane proteins targeted, inserted, and folded
correctly?
How do MPs come to be? How do MPs ﬁnd their ﬁnal
destination and fold properly in a lipid bilayer? This “chicken
and the egg” question has been partially answered over the last
50 years since the PDB was established in 1971. Like all proteins, MPs begin their journey as nascent polypeptides that
emerge from the ribosome with their ﬁnal destination encoded
in their primary structures. Following the discovery that proteins have intrinsic signals encoded in several amino acids near
the emergent N terminus, that govern their transport and
localization in the cell by Sabatini and Blobel in 1971 (132), a
large body of biochemical and functional studies have identiﬁed
the machinery and dissected the steps involved in the sorting,
targeting, and chaperoning of MPs through the cell toward
their ﬁnal destination. Experimental validation of the “signal
hypothesis” led to powerful and widely used computational
methods aimed at predicting the diverse protein-sorting signals
(133) for subcellular compartments or organelles such as the
endoplasmic reticulum (ER), mitochondria, lysosomes or
chloroplasts, and other plastids in all living organisms.
The structural biology of MPs has not only provided
remarkable insights into the architecture and mechanisms of
action of channels, transporters, pumps, and receptors but also
elucidated key aspects of the molecular machinery involved in
their biogenesis: from the targeting and sorting as they emerge
from the ribosome until their translocation across or insertion
into biological membranes. The translocation/insertion step is
catalyzed and assisted by translocons, a general term referring
to the MP machinery facilitating this process. The Sec61/SecY
universal translocon (Sec standing for Secretory) is central to the
translocation of most membrane and secreted proteins while
other “specialized” translocons can be highly substrate-speciﬁc.
Most proteins are thermodynamically stable in their native
state. The process of translocating a polypeptide across or into a
membrane is thermodynamically unfavorable. This is due to the
large entropic costs associated with i) moving polar or charged
amino acids across the inner hydrophobic part of the lipid
bilayer and, conversely, ii) moving hydrophobic amino acids
across the outer membrane surface layers consisting of the
phospholipid polar head groups (134, 135). It is particularly
signiﬁcant for integral MPs with large soluble loops or domains
and complex topological arrangements of hydrophobic TMs. In
the last two decades, the PDB has been the repository of
increasing numbers of structures of soluble and membrane
proteins that help MPs reach their ﬁnal destination and fold
J. Biol. Chem. (2021) 296 100557

7

JBC REVIEWS: Membrane proteins: Celebrating 50 years of the PDB
properly, thus contributing to deciphering the general principles
and mechanisms underlying “protein-assisted” MP biogenesis.
The signal sequence-dependent universal targeting pathway of
membrane proteins
Most MPs follow the Signal Recognition Particle (SRP)
dependent cotranslational targeting pathway (136). At the core
of this evolutionarily conserved machinery is the catalytic and
structural SRP RNA associated with the SRP54 protein. It is
involved in complex assembly, signal sequence recognition,
and nascent chain transfer from the ribosome to the Sec61/
SecY translocon (Fig. 3A). The presence of an RNA component hints at its ancient origin when RNAs played more

prominent roles as catalysts and structural scaffolds in primordial cells (137). Targeting relies on three crucial steps; (i)
the interaction between the Methionine-rich (M) domain of
the soluble SRP54 protein that recognizes and binds N-terminal “greasy” signal sequences as they ﬁrst emerge from the
ribosomal tunnel (138, 139), (ii) the GTP-dependent interaction between the NG (for N-terminal and ras-like GTPase)
catalytic domains in SRP54 and the homologous domains of its
membrane-associated SRP receptor (SR) (140, 141) to form a
targeting complex (TC) at the ER or plasma membranes
resulting in (iii) the delivery of the ribosome-nascent chain
(RNC) from the SRP54/SR complex docked to the translocon
upon structural rearrangement of the SRP54/SR core on its

Figure 3. The machinery of the cotranslational secretion/membrane insertion pathway. A, the SRP-dependent protein targeting pathway (in bacteria).
(1) SRP binds the signal sequence as it emerges from the RNC. (2) GTP-dependent formation of the TC between SRP and its SR receptor at the membrane
delivers the RNC to the translocon (3). The translocon stimulates rearrangement and GTP hydrolysis within the TC and transfer of the RNC from the now
activated TC* to the channel (4) for subsequent secretion or insertion of the translated protein. (5) GTP displaces GDP in SR and SRP to reset the targeting
machinery. B, topology and schematic structure of the protein-conducting Sec61α/SecY large subunit. The ring, plug, and lateral gate of the channel open in
order to accommodate a TM and provide an exit path into the lateral plane of the bilayer. The structure of the closed archaeal SecY (PDB 1RH5) channel
shows where the lateral gate is closed and the pore occluded by the plug helix (magenta) and sealed by the ring of hydrophobic residues (yellow).
Structures of mammalian Sec61 (PDB 3JC2) and bacterial SecY (PDB 3J46) translocons engaged with a nascent chain show the signal sequence (yellow) and
nascent chain (black) emerging from the lateral gate. C, models for the lateral insertion of integral MPs in the lipid bilayer or secretion across the membrane.
TMs of nascent integral MPs initiate their folding within the ribosome tunnel before moving to the Sec61/SecY translocon. In contrast, an unfolded nascent
chain of a protein secreted across the membrane might not trigger opening of the lateral gate. The ring of hydrophobic residues at the constriction of the
hour glass-shaped pore maintains a tight seal around the nascent chain. PTC, peptidyl-transferase center of the ribosome. Accessory complexes of Sec61/
SecY are required for the insertion and chaperoning of multipass MPs.
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SRP RNA scaffold and the channel-stimulated reciprocal GTP
hydrolysis that dissociates SRP from its receptor (142, 143)
(Fig. 3A).
The conserved heterotrimeric channels, Sec61αβγ in eukaryotes or SecYEG in prokaryotes, act as portals and gatekeepers for the insertion of most of the MPs and secreted
proteins. The large subunit forms the protein-conducting pore
itself and is composed of ten TMs, where the ﬁrst ﬁve TMs are
related to the second ﬁve TMs by a twofold quasi-symmetry in
the plane of the membrane (144). This internal pseudosymmetry divides the channel into two halves articulated
around a hinge between TMs 5 and 6 (Fig. 3B). This channel
has a unique architecture with two conducting paths oriented
perpendicular to each other: An hour-glass-shaped pore for
the secretion of proteins across the membrane and a lateral
gate opening to chaperone TMs of integral MPs destined for
insertion into the bilayer and delineated by TMs 2, 3, 7, and 8
(Fig. 3C). The protein-conducting pore is occluded by a short
plug helix and sealed by a ring of hydrophobic residues (Leu,
Ile, and Val) at its constriction point that prevent leakage of
water and ions (145). Structures of free SecY channels with
their lateral gates in different states (146, 147) and structures
of Sec61/SecY channels engaged with different RNCs beautifully illustrate the insertion path followed by nascent TMs of
integral MPs during their biogenesis (148–150). The funnelshaped cytoplasmic vestibule of the translocon is large
enough to accommodate incoming folded helices while soluble
loops can extend at the interface between ribosome and
channel. The α-helical signal sequence of the nascent chain
emerges, opening the lateral gate as it displaces and supplants
TM2. As lateral gate TMs shift, the ring and plug helix are
widened and displaced/unfolded, respectively, to make room
for this nascent chain that contains a folded secondary structure (Fig. 3B).
While the Sec61/SecY protein-conducting channel provides a
clear path across or into the membrane, it is not the sole
arbitrator of MP insertion topology. Proteins start to fold as
soon as space allows, and the ribosome also plays an important
role as the nascent chain can either fold or not, while it elongates from within the ribosomal exit tunnel into the Sec61/SecY
channel (151, 152). Thus, in vivo, rather than start folding inside
a lipid bilayer environment, MPs begin this process within the
ribosome tunnel and the Sec61 translocon, where secondary
structure elements can form and associate into smaller kernels
of tertiary structure (153) and where, perhaps more importantly,
the insertion topology is assigned as the nascent polypeptide
enters into the membrane plane by lateral diffusion. Prokaryotic
and eukaryotic integral MP topologies generally follow the socalled “positive inside” rule for TM orientation as established
by Sipos and von Heijne (154). In this regard, the Sec complex
associated with a ribosome forms an Anﬁnsen cage around the
nascent chain, surrounding the nascent polypeptides with a
protective “enclosure” and environment where folding occurs
unhindered, thus preventing aggregation or misfolding (155).
Although the folding steps occurring in Sec61 remain poorly
understood, lipids do play a role through direct interactions
with the nascent MP in the Sec61 channel (156) (Fig. 3C).

Numerous structures of Sec61/SecY complexes with other
important “accessory” MP complexes such as the Sec62/63,
TRAP (TRanslocon-Associated Protein), and OST (OligoSaccharyl Transferase) (157) in eukaryotes or SecDF (158) and
YidC (159) in prokaryotes have been solved. These structures
reveal that the Sec61/SecY translocon is part of a highly dynamic “MP assembly line,” sometimes referred to as the holo
translocon, with “quality control” mechanisms (160). The
human genome encodes about 2500 multipass MPs (such as
GPCRs, ion channels, and ABC transporters) of considerable
topological complexity. Lateral insertion and folding of such
polytopic MPs require the intervention of Sec61-accessory
complexes such as the Endoplasmic Reticulum membrane
protein complex (EMC). Although our understanding of the
mechanisms governing protein secretion and insertion has
progressed, the speciﬁcs of MP complex assembly into homoor hetero-oligomers still elude us.
The targeting of tail-anchored proteins and new paradigms in
membrane protein biogenesis
Most membrane-inserted proteins harbor an N-terminal
signal sequence, which deﬁnes the main route for protein
targeting and secretion/insertion. A signiﬁcant subset of MPs
uses different routes and distinct protein machineries. Tailanchored (TA) proteins (proteins with a single C-terminal
TM anchor) constitute about 5% of any given eukaryotic
proteome and are targeted with exquisite speciﬁcity to the
diverse organelles (e.g., ER, mitochondria, lysosomes) within
the eukaryotic cell. The yeast Guided-entry of tail-anchored
proteins (Get) pathway, known as TRC in mammals, was
discovered in 2008 (161). It represents a perfect example of a
posttranslational MP targeting system in the ER. TA proteins
do not follow the SRP targeting pathway because they lack an
N-terminal signal sequence. Their targeting signal consists of
their single C-terminal hydrophobic TM, which only emerges
from the ribosomal channel once the rest of the polypeptide
has been synthesized. In yeast, the Get pathway involves at
least six proteins. Among these, the soluble ATPase Get3 and
the two MPs Get1/Get2 are involved in the ﬁnal steps of TA
targeting to, and insertion into, the membrane, respectively
(162, 163, 164). At the late stage of Get targeting, a Get3 dimer
binds the TA of a newly translated TA protein in a hydrophobic groove rich in ﬂexible methionine residues (165), much
akin to the M domain of SRP54. The long N-terminal cytoplasmic end of Get1 captures the Get3/TA complex and targets it to the membrane where the cytoplasmic coiled-coil
extension of Get2 interacts with the docked Get3/TA complex
to stimulate the release of its TA cargo before insertion into
the membrane (166) (Fig. 4A).
The exact mechanism of TM insertion by Get1 (with Get2)
has yet to be elucidated. However, Get1 is a member of the
YidC/Oxa1/Alb3 superfamily of proteins that insert proteins
into membranes in bacteria, mitochondria, and chloroplasts,
respectively (167). This superfamily not only includes the
bacterial insertase YidC but also the widely conserved ER
membrane complex (168–170), which is involved in the
cotranslational insertion of polytopic MPs, such as GPCRs, in
J. Biol. Chem. (2021) 296 100557
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Figure 4. The Guided-entry of tail-anchored proteins pathway. A, simpliﬁed mechanism of the Get pathway and topology of proteins Get1 and Get2.
B, bacterial YidC structure (PDB 6AL2) showing a lipid-exposed hydrophilic groove between TMs 1, 2, and 5 that can be cross-linked to nascent TMcontaining substrates. A simpliﬁed mechanism for YidC (and possibly Get1/2)-assisted insertion of TMs and TA segments into the membrane. For bacterial YidC, membrane thinning and membrane potential facilitate and drive insertion. C, the EMC (PDB 6WW7, 6WB9, 6Z3W) translocates multipass MPs and
some TA proteins. TMs follow a gradient of increasing hydrophobicity from the hydrophilic cytosolic vestibule into the intramembranous hydrophobic
groove acting as a lateral opening for insertion into the lipid bilayer.

association with the Sec61 translocon, and also the posttranslational insertion of some more hydrophilic TA proteins.
In particular, EMC assists Sec61 with the insertion of MPs
with complex topologies and destabilizing features in their
TMs such as charged residues (171). Remarkably, the structure
of another Sec61-associated complex containing ﬁve accessory
factors (TMCO1-CCDC47 and Nicalin-TMEM147-NOMO),
distinct of EMC but also involved in the biogenesis of hundreds of multipass MPs was recently solved (172). TMCO1 is
also a member of the YidC/Oxa1/Alb3 superfamily. The
structures of these machineries involved in complex MP
biogenesis were determined within the last 2 years.
Unlike the posttranslational insertase Get1/2, YidC, and
EMC cooperate with the SecY/Sec61 translocon for the
insertion of MPs. Based on the structure of bacterial YidC
(173), a model for the insertion of TMs and TAs has emerged.
A “hydrophobic slide” is created between TMs 1, 2, and 5,
while the hydrophilic environment generated by the groove
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can recruit the extracellular regions on substrates into the lowdielectric environment of the membrane, thus facilitating
insertion (Fig. 4B). Furthermore, the protein architecture and
its interactions with membrane phospholipids result in an
asymmetric thinning of the membrane on the cytoplasmic side
near the aqueous membrane cavity (174).
The nine-subunit structure of EMC reveals that TMs from
subunits EMC3, 5 and 6, form a lumen-sealed lipid-exposed
intramembranous groove large enough to accommodate a
single TM, similar to YidC. Furthermore, protein translocation
involves a cytosolic hydrophilic vestibule (EMC2/EMC8-9) at
the interface between EMC2 and EMC3, EMC5 and EMC6,
and methionine-rich loops on EMC3 to probably accommodate the bulkier and more hydrophilic ends of TA proteins and
capture their hydrophobic TA, respectively. EMC uses spatially
distinct yet coupled regions including lipid-accessible membrane cavities and cytosolic surfaces to function as an insertase
for TA proteins and a protein holdase-chaperone for complex
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polytopic MPs (175). Increasing hydrophobic interaction between the hydrophilic cytoplasmic vestibule and the buried
hydrophobic membrane groove guides the translocating TAs
for insertion (170). Membrane thinning around the EMC
further lowers the energy barrier for translocation (Fig. 4C).
While the Get machinery targets client proteins with highly
hydrophobic TAs, the EMC seems to prefer TA proteins with
lower hydrophobicity. Thus, triage of TMs and TAs into the
different insertion machineries (i.e., EMC versus Get) relies, at
least in part, on their relative hydrophobicity (171, 176). These
recent structures illustrate the roles of electrostatics, hydrophobicity, and protein architecture in establishing the topology
of TM translocation through shaping and thinning of the
surrounding membrane to facilitate insertion.
Folding it backward: The case of β-barrel transmembrane
proteins
Helical MPs are ubiquitous in prokaryotes and eukaryotes.
Transmembrane β-barrel proteins constitute another functionally important class of integral MPs composed mostly of
membrane-spanning β-strands; they are exclusively found in
the outer membranes of Gram-negative bacteria and the
membranes of mitochondria, chloroplasts, and other plastids
in eukaryotes. The transmembrane β-barrel scaffold is based
on an antiparallel sheet of β-strands (usually an even number) arranged into a cylindrical structure delineating a central and functional pore or cavity. The ﬁrst transmembrane
β-barrel protein structures, PhoE and OmpF, were solved in
1991 to 1992 by the Jansonius/Rosenbusch and the Schulz
groups (177, 178). Because of their cellular localization, the
biogenesis of β-barrel proteins is essentially posttranslational (179). What about membrane insertion of βbarrel proteins?

The bacterial β-Barrel Assembly Machine (BAM) (180),
related to the mitochondrial Sorting and Assembly Machinery,
accelerates folding without using exogenous energy (such as
ATP or membrane potential). A recent cryo-EM structure
(181) reveals a “templating” mechanism based on sequential βaugmentation for the folding and insertion of β-strands into
membranes and the growth of the cylindrical β-barrel structure. The BAM complex is composed of the membranous
subunit BamA and four lipid-binding soluble proteins
(BamBCDE) (180, 182). The central component BamA is itself
a β-barrel protein that forms a closed 16 β-stranded antiparallel barrel when not engaged with a substrate (Fig. 5A).
The structure of BamA trapped with a model β-barrel
substrate (a modiﬁed version of its barrel) shows that the
active BamA barrel is splayed open along its lateral gate,
exposing the two N-terminal strands β1 and β2. The N-terminal β1 strand no longer hydrogen bonds with C-terminal
strand β16, as seen in the resting structure of folded BamA.
Instead, it forms six hydrogen bonds with the C-terminal
strand β16 of its barrel substrate protein (Fig. 5B). However,
the resulting hybrid barrel is asymmetric since the C-terminal
strand β16 of BamA does not pair with the N-terminal β1
strand of the barrel substrate. By binding the N-terminal edge
of BamA as an extended β-strand, the C terminus of the
substrate forms a new edge that serves as a template to guide
binding and folding of the subsequent β-strand by βaugmentation. As a consequence, folding is directional and
proceeds from C- to N terminus (Fig. 5B). Interestingly, the six
hydrogen bonds between strands in the membrane environment form a very stable interface between the two proteins,
BAM and the nascent β-barrel substrate. Such stability enables
folding but results in a high kinetic barrier for substrate release
once folding is complete. Sequence features at each end of the

Figure 5. Bacterial β-barrel membrane proteins biogenesis by BAM. A, the BAM complex catalyzes posttranslational insertion of transmembrane
β-barrel proteins from the periplasm into the bacterial outer membrane. Superposition of the β-barrel domain of BamA in the resting (PDB 4N75) or active
(*) states (PDB 6V05) with a nascent β-barrel protein. B, C-to-N terminal β-barrel folding by sequential β-augmentation.
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substrates overcome this barrier and favor substrate release by
stepwise exchange of hydrogen bonds (181). More recently,
two cryo-EM structures of the Sorting and Assembly Machinery, structurally and functionally related to BAM, also
revealed an opening of the lateral gate as substrates get
inserted and suggested that entire precursor proteins might
fold using a β-barrel switching mechanism (183, 184).
The general dogma is that translocons must harness some
form of energy to lower the energetic barrier associated with
the translocation of a polypeptide and to function as translocases and/or insertases. The most common energy sources
for such processes are the binding and hydrolysis energy of
nucleotides (i.e., ATP and GTP) and also proton gradients or
membrane potential that can impart directionality. In particular, ATPases such as the SecA ATPase, which energizes the
SecY-dependent posttranslational protein secretion in bacteria
(185), or AAA+ ATPases speciﬁc to secretion systems found in
pathogenic bacteria or protozoa, couple ATP binding and
hydrolysis energy to generate mechanical forces used to unfold
and translocate their substrates. These translocons use socalled polypeptide “clamps”; they engage the polypeptide
main chain nonspeciﬁcally and keep it unfolded as it is
threaded through a proteinaceous pore traversing the membrane. The recent structures of the EMC and BAM machineries reveal in exquisite detail how protein-assisted
translocation and insertion combine mechanisms such as
membrane thinning, hydrophobic sliding, and protein-templating to decrease the energetic barrier associated with
translocation across or insertion into the bilayer of a polypeptide without apparent expenditure of energy.
Most extreme translocation: Effector protein and virulence factor
secretion in pathogens
The journey of some secreted proteins across the cell can be
more arduous in the extreme cases of intracellular pathogens
such as the deadly malaria parasite Plasmodium falciparum
(Pf). Malaria is a disease mentioned in Sumerian and Egyptian
ancient texts (1550 BC). In 2018, Plasmodium infected some
230 million humans and claimed about 435,000 lives. Upon
infection of its human host, this obligate intracellular parasite
dwells within a parasitophorous vacuole derived by invagination through the membrane of infected hepatocytes or erythrocytes. Plasmodium is a master cell renovator; it exports
hundreds of effector proteins and virulence factors across the
PV membrane into the host cell in order to gather nutrients,
eliminate waste, persist and thrive in its host, and evade the
immune response (186, 187). Some of these exported proteins
belong to a Plasmodium “transportome” (188)—a compendium of transporters, pumps, and channels involved in ion
ﬂux, nutrient/metabolite import, and waste/drug efﬂux within
the parasite and the infected host cell such as the hexose
transporter PfHT1 and the chloroquine-resistance transporter
PfCRT. In 2009, de Koning-Ward et al. (189) discovered the
complex responsible for vacuolar secretion and named it
Plasmodium translocon of exported proteins (PTEX) (Fig. 6A).
PTEX is composed of three essential core subunits: The
pore-forming protein EXP2, the AAA+ protein unfoldase
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HSP101, and the adaptor PTEX150. Two accessory subunits,
PTEX88 and TRX2, complete the assembly (190, 191). Its
cryo-EM structure revealed the architecture of its ternary core
(192), including the novel MP structure of EXP2 that forms the
protein-conducting pore (Fig. 6B). Most of the effector proteins are essential to parasite survival. Thus, the vacuolar
secretion pathway, with its Plasmodium-speciﬁc and unique
vacuolar translocon, provides prime targets for the design of
novel antimalarial drugs (191, 193, 194).
The 1.6 MDa PTEX complex solved by Ho and Beck was
obtained from endogenous sources, expressed at its natural
(low) abundance, and extracted directly from human red blood
cells infected with Plasmodium parasites CRISPR/Cas9-edited
to express HSP101 bearing an afﬁnity puriﬁcation tag at its C
terminus. While puriﬁcation from endogenous sources is not a
novel strategy per se, the clever use of CRISPR/Cas9 gene
editing by Beck and Goldberg (195) on an “unruly” organism
such as Plasmodium, traditionally recalcitrant to facile genetics, opens new frontiers to tackle the structures of scarcely
available complex molecular machines that could not be
reconstituted using more traditional approaches based on recombinant expression. Furthermore, extraction of the endogenous PTEX structure in the presence of the slowly
hydrolysable nucleotide analog ATPγS allowed the complex to
be caught “in the act” under two distinct states engaged with
endogenous cargo trapped in the translocation channel of the
HSP101 ATPase (Fig. 6B). It provided valuable insights into
the mechanism of effector secretion. PTEX is an example of
purely posttranslational translocon and, in contrast with
Sec61/SecY, it seems devoid of insertase function and exclusively provides a path for posttranslational secretion across the
vacuolar membrane (191). This example illustrates the power
of a “shotgun” approach combining cryo-EM (or cryo-ET) and
Mass-Spectrometry-based proteomics to isolate, identify, and
resolve ensembles of large macromolecular assemblies in
complex mixtures such as crude cellular extracts (196).
Each of these structures brings us back to our “chicken and
the egg” problem. During the emergence of life from primordial macromolecular systems, it is likely that primitive MPs
spontaneously inserted in simple lipidic bilayers. Spontaneous
insertion of very hydrophobic TMs has been observed for MPs
with relatively simple topologies. The emergence of a translocon with its accessory factors and protein quality control
machinery probably paralleled increasing complexiﬁcation of
MP folds, cellular compartmentalization, and the associated
evolutionary pressure to evolve more sophisticated and dynamic proteinaceous systems to catalyze and chaperone their
folding and proper biogenesis. In-depth analyses of the YidC
and SecY structures and of the requirements for the biogenesis
of different classes of integral MPs and secreted proteins shed
light on the origins and evolution of the most ancient “translocators.” Lewis and Hegde speculate that SecY originated as a
YidC homolog formed of two hydrophilic grooves juxtaposed
within an antiparallel homodimer (197). The proposed “molecular ﬁliation” between the two major MP biogenesis factors
offers a new perspective on a fundamental step in the evolution of macromolecular biological systems and cells.
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Figure 6. The Plasmodium translocon of exported proteins acts as the essential nexus for protein export and host cell remodeling by the malaria
parasite. A, effector proteins and virulence factors are secreted across the encasing parasitophorous vacuole membrane (PVM) inside the host red blood
cell (RBC) by the genus-speciﬁc Plasmodium Translocon of Exported proteins (PTEX) whose core is composed of subunits EXP2, PTEX150, and HSP101.
B, cryo-EM structures of two distinct states (PDB 6E10, 6E11) of the ternary PTEX core complex. Both are trapped with endogenous cargo polypeptide
engaged in the translocation path of the spiral staircase hexameric assembly of HSP101 (rainbow subunit-coloring pattern) sitting atop of the membrane
inserted PTEX150/EXP2 tetradecamer (gray). The labile auxiliary subunits TRX2 and PTEX88 were not present in the ﬁnal reconstructions. Slice-through view
of the HSP101 ATPase in the open state showing endogenous cargo (pink) clamped by each tyrosine of the pore loops (red) arranged into a spiral staircase.

Water transport by aquaporins and ammonia gas transport
by the Rh family
The AQPs provide a striking example of how, over
two decades, the PDB coordinated structures into functional
knowledge. Because life depends on water, regulation of water
movement across cells without leakage of any ions or protons
is an essential function. It is encoded in a family of highly
regulated water channels that are expressed in the organ, tissue, and cell-speciﬁc locations (198). By the 1960s, there was
evidence that water permeated membranes faster than through
lipid bilayers. Red blood cells conducted water with a low
activation energy barrier, while oocytes had very high resistance to conductance. Benga and colleagues showed in 1986
that this water conductance could be inhibited by p-chloromercuribenzoate. The reversal of this inhibition by reducing
agents implied a protein channel that contained a sulfhydryl
accessible to mercury ions (49, 50, 199). While radiation
inactivation correctly predicted a channel of 30 kDa in size
(200), Agre (201), in a search for Rh blood group antigens in
highly porous red blood cells, found two protein bands—one
of 32 kDa and the other 28 kDa. Expression cloning in frog
oocytes of the 28 kDa “Channel-like Integral membrane Protein of 28 kDa” (CHIP28) (202, 203) from an erythroid library
showed that transfected oocytes responded to reduced osmolarity by swelling and lysing, while control oocytes barely
swelled at all (48). The gene responsible was shown to be
similar to others in microbes and plants (204), and Agre
named the family the Aquaporins. CHIP28 became AQP1. It
was shown to be a tetramer (205, 206) with a permeability
estimated at a remarkable 3 × 109 water molecules per second
(207, 208), which equated to the diffusion limit for a pore the
size of a single ﬁle of water molecules. More AQP homologs

were discovered and the family provided essential functions
represented in all living species from bacteria to humans (198,
209).
In the same family, the aquaglyceroporins that conduct
small organic alcohols including glycerol as well as water are
interesting because of the clear need for this function (210).
AQP3 is permeable to glycerol and water while AQP9 has even
broader speciﬁcity. There is also an ion-conducting AQP.
AQP6 conducts water poorly and is unique in conducting ions
through the same water-conducting channel, supported by
altered sequence in the pore, or possibly through the fourfold
axis of the tetramer (54, 211).
The ﬁrst atomic structure of an AQP was determined in
2000 for the Aquaglyceroporin GlpF by X-ray diffraction at
2.2 Å resolution (54). AQP1 was deﬁned by electron crystallography of 2D crystalline arrays of AQP1 at 3.8 Å resolution
(53), followed closely by the X-ray structures of AQP1 at 2.2 Å
(212, 213) and bacterial AqpZ at 2.5 Å (214). The structures
showed AQPs to be fourfold symmetric tetramers in which the
water channels lie within each monomer and not between
monomers or along the symmetry axis (Fig. 7). There are now
60 structures reported in the PDB with some at sub Å resolution (215). AQP structures AQP0 and AQP4 were determined by X-ray crystallography (55, 216) and by electron
crystallography (217, 218) of natural 2D crystalline arrays of
the tetramers that are found in certain specialized environments. Natural arrays from an ordered region of the eye lens
led to 1.9 Å structure for AQP0 that showed the position of
lipids that supported the crystalline array in membranes.
The structures show an uninterrupted line of permeant
waters within each monomeric channel across the entire
membrane. These water molecules are hydrogen bonded to
J. Biol. Chem. (2021) 296 100557
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proposals, showing that “turning off” the helix dipoles reduced
the tendency to bipolarize the channel waters (219). The absolute rejection of any ions, even hydronium ions or protons,
through the line of waters has attracted conﬁrmatory molecular dynamic (MD) simulations up to over 100 ns using
increasingly sophisticated empirical valence bond and electrostatic approaches (222, 223).
The 13 AQPs in humans each have highly differentiated
roles in physiology. This is even more so in plants with 38
AQPs in Arabidopsis thaliana (224)! Genetic knockouts
allowed insight into the unrecognized importance of some of
these aquaporins (225). AQP structures became robust models
for MD simulations due to their range of conductance and
speciﬁcities for small neutral organic molecules. MD simulations and electrostatic calculations allow understanding of the
impact of dynamics, electrostatics, and dehydration penalties
in Biology, readily accounting for water conductivity at close to
the experimental levels of 109 molecules per second, and
speciﬁcities e.g., how conversion of one histidine in the wateronly aromatic arginine SF to a hydrophobic side chain allows
small neutral organic compounds to pass in speciﬁc
Figure 7. The aquaporin channel. A, line of waters in human AQP4 at 1.8 Å aquaglyceroporins.
resolution (PDB 3GD8). B, single monomer of AQP4. C, the tetrameric
How do the AQPs exclude passage of hydronium ions or
arrangement in all AQPs places four channels in each tetramer. Panels
protons hopping through the line of waters by the Grotthus
derived with permission of the PNAS from Ho et al. (55).
mechanism (101, 102)? The theoretical energy proﬁle seen by a
proton or a hydronium ion passing through the channel shows
each other in line and sideways as hydrogen bond donors to a that the highest barrier is an electrostatic one where the two
line of eight carbonyl oxygens of successive amino acids— -NPA-regions meet, along with the helical dipoles that
like pitons that form a line all the way to and from the augment the polarization of the central water (226–229).
polarized central pair of water molecules (219, 220). Substrates Mutations and simulations show that the SF also provides
entering from the outside meet an SF formed by a highly electrostatic repulsion to positive ions or protons (229).
oriented guanidinium side chain of arginine that projects However, a hydronium (or any other) ion, on approaching the
hydrogen bond donors and positive charge into the pore and entry to the channel, needs to be partially dehydrated to enter.
against a hydrophobic aromatic corner opposite the arginine. This requires a potentially insurmountable large energy cost
This region, termed the aromatic arginine (aR) region that would need to be compensated for by the structure of the
SF, distinguishes between water alone and water plus other protein pore (230). In addition when a proton is forced
small substrates. Aquaglyceroporins are specialized by two through the channel, the protein requires sufﬁcient time in the
aromatic side chains that form a hydrophobic corner opposite simulation to adapt to stabilizing the proton and reduce the
to the aR in this region to conduct small organic neutral apparent barrier at the channel center (231). The negative
molecules including glycerol and urea as well as water. While charge on the membrane surface may also contribute to
compensated for by surrounding acidic side chains, the aR repulsion of ions. It is argued however that the “reduced solpositive charge presents an essential electrostatic barrier to vation” requirement is the dominant energetic term in aquaporins (232).
passage of all positive ions (Fig. 7A).
How is it that other channels also support a continuous line
The central channel waters are oriented by two highly
of
water molecules and do readily conduct hydronium ion?
conserved asparagine N-H hydrogen donors within highly
The
Gramicidin D (A, B, C) channels, antibacterial channels
conserved -asparagine-proline-alanine- (-NPA-) regions that
consisting
of opposed helices of 15 amino acids that meet in
abut each other in a “ﬁreman’s grip” structure, to force the
the
mid-membrane
plane, kill cells by freely conduct protons
central water molecules to be hydrogen bond acceptors and
or
hydronium
ions.
So where is the key difference? The carorient their hydrogens always away from the center. This is
bonyls
of
amino
acids
in Gramicidin generally point more
augmented by the positive dipoles of the two half helices that
outward
than
in
the
AQPs
and therefore better accommodate
begin with the -NPA-region and stretch diagonally outward to
the
incoming
hydronium
ion hydration shells (233–236).
the two surfaces of the bilayer. This arrangement polarizes the
While
the
dehydration
cost
for ions limits access to these
central water molecules so that their hydrogen atoms point
channels
too,
it
is
the
polarization
of waters that deﬁnes
away from the center, then polarizing the entire line of water
aquaporin
selectivity
for
water
and
prevents
leakage of any
molecules out to the membrane surface (54, 215, 221). Early
simulations over 300 ps time scales validated these charged ion or protons. Such examples exquisitely illustrate
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how structural information informs critical aspects of the
function that were otherwise not accessible or understandable
any other way.
The phylogenetic tree shows that AQPs diverged into the
water and the water plus glycerol branches among bacteria and
then diverged into its many tissue-speciﬁc variants that
perform essential functions. The common scaffold provides a
remarkable data set of interactions that show how speciﬁcity is
encoded in subtle variations in structure. The AQPs provide
the most intricate insights into the character and properties of
water–protein interactions and the barriers to proton transfer
through hydrogen bonded lines or waters in all of biology.
Ammonia like water has a similar size and dipole moment as
water and its management is crucial in physiology. How is it
conducted? Ammonia/ammonium conduction is mediated by
a separate ammonia transport family (AmT family in bacteria,
Rh family in humans) from a genomic background completely
unrelated to the AQPs. AmT/Rh proteins are all trimers of
12 TM proteins (237, 238), in which each monomer conducts
neutral NH3, although there is a controversy that they might
also act partially as ammonium ion transporters. In the AQPs
speciﬁcity against the ammonium ion lies in the cost of
dehydrating the ionic NH4+ form. The more hydrophobic
channel in AmT/Rh helps by destabilizing the ionic form by
reducing the pKa of ammonium ion from 10 to <5 as it
enters the Amt pore.
How do ions cross the membrane? Insights from structures of
ion channels
The intrinsic impermeability of the membrane to ions creates two challenges for biology. First, how do ions cross the
membrane? And second, how are such movements controlled?
As we illustrate here, the availability of the structures of MPs
(i.e., ion channels) controlling such processes have played key
roles in elucidating how nature’s design harnesses the unique
properties of membranes for biological functions.
Ever since Hodgkin and Huxley described their electrical
properties in the 1950s (44, 45, 239–241), proteins that enable
the axon membrane to change its permeability to Na+ and K+
have been under intense scrutiny. In the 1970s, Armstrong and
Hille ﬁrst demonstrated that Na+ and K+ cross the membrane
through different proteins with pores that select for their
respective ions, i.e., the Na+-channels and K+-channels (242–
244). With the advancements in molecular cloning methods,
the genes encoding Na+-channels and K+-channels were
cloned in the 1980s (245–249). Meanwhile, the ingenious use
of natural toxins and small molecules that bind and inhibit K+channels and Na+-channels also allowed the groups of
MacKinnon, Miller, and Catterall to purify K+- and Na+channels and deﬁne their architectures (250–255). Biochemical investigations together with sequence analysis of
additional channels plus mutagenesis studies quickly led to the
identiﬁcation of the signature sequences for the pore, the SF,
and the gate (256–262) in the late 1980s. Using knowledge
acquired over 40 years by numerous investigators in the ﬁeld,
MacKinnon concluded in 1995 that K+-channels must be
tetrameric with their pore loops entering the central

conductance pathway encircled by the four subunits (Fig. 8A)
(263). However, how ion channels achieved both incredible
selectivity and conductance at the same time remained a
mystery. In particular, this model could not answer the critical
question of how K+-channels conduct K+ ions with a Pauling
radius of 1.33 Å but exclude the very similar Na+ ion with a
smaller Pauling radius of 0.95 Å. MacKinnon concluded, “the
answer to this question would require knowing the atomic
structure formed by the signature sequence amino acids”
(264). The atomic structure of a bacterial homolog of the
mammalian K+-channels, KcsA, indeed provided the answer
just 3 years later in 1998 (47, 263). The SF of KcsA perfectly
replaces the bound water molecules around a K+ ion entering
the channel while the carbonyl oxygens of the SF are too far
apart to correctly hydrate the Na+ ion.
Subsequent high-resolution structures of KcsA and Na+channels conﬁrmed this hypothesis and provided further
molecular detail (265–268). The structures of the SF of the K+channels are composed of four backbone carbonyl groups
from each subunit arranged into a long neck that perfectly
matches the coordination conﬁguration of a K+ ion in water
(Fig. 8B). Dehydrated K+ ions in the ﬁlter are coordinated by
eight oxygen atoms provided by the carbonyl groups, replacing
the eight water molecules lost. This results in a minimum
energy cost for a K+ ion to lose its bound waters in the solvent
and to enter the SF. On the other hand, the preference of Na+
ion to bind to six water molecules in an octahedral conﬁguration does not match the structure provided by the SF in the
K+-channels. The energetic cost for Na+ to lose its bound
water thus excluded it from entering the narrow pore. The
long SF provides 4 K+ binding sites. High conductance is
achieved through electrostatic repulsion between the positively
charged K+ ions that pushes the ions through the ﬁlter. As a
result, sites 1, 3 and 2, 4 are occupied by 2 K+ ions in an
alternating fashion. Na+-channels on the other hand conduct
Na+ ions in their partially dehydrated form with a wider and
much shorter SF ﬁlled with water (Fig. 8C). The highly negatively charged ﬁlter and pore in Na+-channels would attract
positively charged anions. Compared with K+ ions, the smaller
Na+ ions would approach more closely this site of high ﬁeld
strength located at the extracellular mouth of the channel, with
their preferred partial dehydration enabling entry into the SF
and ion conductance pathway.
Activities of ion channels can be regulated in various ways
(269). The nonequilibrium charge distribution due to the
impermeability of the membrane itself results in an electric
ﬁeld across the membrane. As a result, regulation by voltage is
one of the most common ways ion channels control their
activities. Some channel proteins, such as the Na+-channels
represented by the voltage-gated Na+-channel from Arcobacter
butzleri (NavAb), can sense this electric ﬁeld using charged
residues embedded within the bilayer that move in response to
changes in the magnitude or polarity of the ﬁeld (269, 270).
This conformational change can be coupled to dilation of the
central pore for ions to diffuse through, as in the case of
voltage-gated ion channels (VGIC). In some cases, enzymatic
activity or other unexplored biological functions are used. All
J. Biol. Chem. (2021) 296 100557
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Figure 8. Architectures of ion channels revealed by structures. A, the proposed architecture of the tetrameric K+-channels and their pore loops before
structures were available (reproduced with permission (263)). B, high-resolution crystal structure of KcsA with bound K+ ions in and around the SF (PDB
1K4C). Four dehydrated K+ ions are coordinated by backbone carbonyls from the SF (Although only 2 K+ ions occupy position 1, 3 or 2, 4 in the SF at any
given time, all four are observed in the crystal structure as the structure represent the average between the two states). One K+ ion coordinated by eight
waters is observed right below the SF in the cavity while two more K+ ion, one completely dehydrated and one partially dehydrated, are observed above
the SF. C–E, crystal structure of NavAb (PDB 5VB8). Structure of S5–S6 and the SF is shown in (C) while the structure of NavAb is shown in (D). Water
molecules bound to the Na+ were not resolved in the structure. For clarity, the two subunits in the front and back are removed in (B) and (C) while the two
VSDs in the front and back are removed in (D). The outer helix of KcsA (the equivalent of S5 of Shaker) is colored in light blue while the inner helix (the
equivalent of S6 of Shaker) is colored in light green and the pore region is colored in light yellow in (B). K+ ions are shown as purple spheres while waters are
in red. In panel (C–F), the VSDs composed of S1–S4 are colored in pink; S4–S5 linker is colored in orange; S5 is shown in blue while S6 is shown in green; the
pore region is colored in yellow. E, a single subunit of NavAb in the activated state where R1–R3 are above the HCS. F, the functional subunit of TPC3 (PDB
6V1Q) in the resting state where only R3 is above the HCS. The voltage-sensing residues located on S4 are shown as magenta sticks in panel E and F while
the acidic residues they interact with at the ENC and INC are colored in green. The residues forming the HCS are colored in cyan. Membranes are indicated
with the black line.

known so-called voltage-sensing domains (VSDs) are
composed of four TMs arranged in a bundle (pink in Fig. 8, D–
F), with at least one positively charged residue (magenta in
Fig. 8, E and F) located within the bilayer. If a VSD contains
multiple gating charges, these are typically arranged in an i,
i+3n pattern along the helical path (Fig. 8, E and F).
In addition to gating charges that project into the four-helix
bundle, VSDs often share a number of common structural and
biophysical characteristics (Fig. 8, E and F). The chargebearing gating helix (S4 in the Shaker cassette) often adopts
a 310 helix in order to stack the basic residues above one
another. The four-helix bundle also contains a hydrophobic
seal, also called the hydrophobic constriction site (HCS) or
gasket (cyan in Fig. 8, E and F), which lowers the dielectric
constant of the bundle and prevents leakage of ions and water
through its center. Finally, negatively charged residues, denoted as the extracellular and intracellular negative clusters (ENC
and INC), are often situated at either extreme of the VSD and
can establish salt bridge interactions with the gating charges.
The conformational response of VSDs to changes in the
trans-membrane electric ﬁeld has been the subject of decades
of biophysical and structural investigation. Armstrong and
Bezanilla were the ﬁrst to report “capacitive gating currents,”
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whereby the current elicited by gating charges moving across
the membrane was directly observed (271, 272). These currents suggested that the gating charges likely move in a direction coincident with the transmembrane electric ﬁeld
vector. While the voltage-dependent dynamics of VSDs can
be partially inferred by ﬂuorescence measurements or
chemical modiﬁcation experiments (273, 274), direct visualization of these conformational transitions has not been
possible simply because it is not possible to impose electrical
gradients across the VGIC in either a lattice state suitable for
X-ray diffraction or as a dispersion of single particles for
cryo-EM. Therefore, the only states of the voltage-dependent
specimen accessible to structural techniques are those that
exist at 0 mV potential.
Early structures of voltage-gated K+-channels (KV channels)
at 0 mV potential suggested that the vertical motion of S4
couples directly to the S5 pore helix via a S4-S5 linker helix,
which is situated in the plane of the membrane (275). As S4
moves upward, it tugs on the S4-S5 linker and in turn S5,
causing the pore to dilate in a process known as electromechanical coupling (Fig. 8, E and F). Later structures of prokaryotic voltage-gated Na+-channels (NaV channels) allowed
for structural comparison of VSDs (266, 276, 277). While the
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overall structure of the VSDs was remarkably conserved, the
observed orientations of the VSD with respect to the pore
domain differed between channels. This was conﬁrmed in the
structures of two-pore channels where the VSD can move as a
rigid body with respect to the pore domain, in addition to
undergoing canonical charge transfer (79, 278). Unlike most
VGICs that are activated at 0 mV, the two-pore channel 3
(TPC3) is only activated at extremely high voltage (V50  +
75 mV). The recently determined cryo-EM structure of TPC3
thus provides a unique opportunity to “see” a VGIC at resting
state at 0 mV where the cryo-EM structure is captured (278).
Consistent with the earlier hypothesis, S4 adapts a down position where only one out of the three arginine residues is
above the HCS (Fig. 8F). In comparison, three out of the four
arginine residues on S4 of NavAb are above the HCS, representing an activated state (Fig. 8E). Both structures conﬁrm
that S1–S3 also play critical roles in voltage sensing by
providing residues in the ENC and INC that would stabilize
the S4 in either the activated or resting state through salt
bridge formation involving the arginines.
The ability to see the inner working of an ion channels by
determining their atomic structures was critical for understanding how these amazing machines elegantly perform their
functions that underly various essential biological processes.
With more than 852 structures of ion channels in the PDB, we
now understand how different ions selectively cross the
membrane through speciﬁc ion channels and how their activities are regulated. As many ion channels have been implicated in various diseases, molecular understanding of their
mechanisms and ready accessibility of their structures in the
PDB are playing critical roles in the hope of treatments that
target ion channels.
How do vertebrate tissues prevent the passage of molecules
through the spaces between neighboring cells? Claudins are
molecular gatekeepers between cells.
In epithelium and endothelium, spaces exist between cells
but molecules are restricted from unfettered transport. The
restrictions imposed on these molecules force them to enter
cells via transcellular transport mechanisms instead of passing
between them. Vertebrate epithelium and endothelium regulate molecular movements between adjacent cells, paracellular
transport, at narrow strands beneath the apical surface at
specialized cellular contacts called tight junctions (TJs). As
compartments within tissues require molecular exchange to
maintain homeostasis, TJs assist here by forming membraneassociated multiprotein complexes to govern paracellular
transport. The assembly of several families of MPs at TJs,
speciﬁcally, creates either barriers or charge- and size-selective
pores to small molecules and ions. The molecular properties of
a given tissue or cell type, therefore, are determined by the
MPs that assemble their TJs. As some molecules are only
transported by paracellular means, regulation of this transport
mechanism by TJs is critical to certain biological processes.
Molecular transport through the paracellular space may have
evolved in animal tissues as an energy conservation strategy, as
a result of aerobic respiration. Impairing paracellular transport

in mouse kidney results in normal ion absorption but
increased oxygen consumption and hypoxia, demonstrating
that the transcellular transport pathway alone is less energy
efﬁcient and that paracellular transport enhances kidney efﬁciency (279).
TJs were identiﬁed in 1963 by EM analyses of mammalian
epithelial cells (280), but it was not until 1993 (281) and 1998
(282) when Tsukita and coworkers established the essential
roles of integral MPs in TJ structure and function. Only one
group of integral MPs, claudins (CLDNs), were capable of
reconstituting TJ strands in TJ-less ﬁbroblasts (283), distinguishing them as the structural backbone of TJs. Soon after,
these were shown to be cell/cell adhesion molecules (284),
which hinted at an ability to interact across paracellular space.
The discovery of CLDNs led to newfound insights into the
diverse functions of TJs and how these functions were enabled
by CLDNs. These functions range from maintaining salt/water
balance in ﬁsh gills (285), forming barriers in human skin to
prevent dehydration (286), to sealing the blood–brain barrier
—highly selective interfaces that provide a defense for the
brain against pathogens and toxins in the blood (287). The
plethora of TJ-linked diseases further demonstrates the diversity of TJ functions and how errors in TJ protein assembly
contribute to these disorders, which include cancer (288–290),
Alzheimer’s (291, 292), Parkinson’s (293) and Huntington’s
(294) disease, amyotrophic lateral sclerosis (295), stroke (296),
food poisoning (297) and irritable bowel disease (298, 299),
hepatitis (300, 301), and diseases of the skin (302–305), kidney
(306–308), eyes (308–310), and ears (311–313).
Identiﬁcation of the ﬁrst two CLDNs led to subsequent
classiﬁcation of a CLDN family and the prediction of four TMs
by cloning and sequence hydrophilicity analyses (314). In
vertebrates, mammals have at least 24 subtypes, humans
possess 27 (315), while pufferﬁsh of the genus Takifugu have
56 claudins (316). Human CLDNs range in size from 23 to
34 kDa and are classiﬁed by a conserved WGLWCC motif. In
addition to four TMs, most CLDNs contain a short N terminus
and variable length C terminus and one intracellular and two
extracellular segments (ECS). The two ECSs vary in length
between subtypes, but ECS1 is larger and contains a conserved
C54–C64 disulﬁde bridge. CLDN topology facilitates TJ assembly through: i) lateral CLDN/CLDN interactions within
the same membrane (cis), ii) paracellular interactions with
CLDNs on adjacent membranes (trans), and iii) cytoskeletal
anchoring by soluble scaffolding proteins (317). Trans interactions between the ECS of adjacent CLDNs form paracellular barriers or pores to small molecules and ions. Because
CLDN subtypes have speciﬁc permeability characteristics and
tissue expression patterns, it is thought that the combinations
and ratios of CLDN subtypes in given tissues’ TJs determine
tissue barrier or pore properties. CLDNs are indeed classiﬁed
by their barrier or pore-forming nature (318) and can be
further delineated by levels of homology outside of the
WGLWCC motif (319).
In April 2013, Suzuki et al. (320) uncovered the ﬁrst 7 Å
structure of a CLDN-like protein from the single-cell ﬂagellate
Euglena by electron crystallography. This protein, IP39, was
J. Biol. Chem. (2021) 296 100557
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predicted to have four TMs and a WGLWCC motif. Although
the resolution of the IP39 structure obtained from 2D crystals
was insufﬁcient to determine the fold, the 3D EM density map
revealed unique arrangements of IP39 in the lattice. IP39
molecules were packed in strands of antiparallel double rows,
with trimeric units longitudinally polymerized, and one
molecule of the trimer rotated 180 from the other two. These
interactions were hypothesized to be important for linear
polymerization of IP39 on Euglena membranes and potentially
for TJ strand formation based on IP39’s sequence and topology
similarity to CLDNs.
One year later, Suzuki et al. (321) determined the ﬁrst
structure of a CLDN by X-ray diffraction at 2.4 Å resolution.
Mouse CLDN-15 (mCLDN-15) is a cation-selective poreforming CLDN (322, 323). To obtain 3D crystals of mCLDN15, they employed a newer MP crystallization strategy, LCP
(324), using a construct truncated of 33 amino acids at its C
terminus and lacking four palmitoylation sites. The structure
revealed the CLDN fold, which is composed of four TMs arranged in a left-handed bundle, one unstructured intracellular
segment connecting TM 2 to 3, and two ECS linked together
by a 5-stranded anti-parallel β-sheet (Fig. 9A). Unresolved in
the structure was the loop connecting strand β1 to β2 and the
N terminus, while two monooleins were resolved and located
near F11 and W49. The crystal structure suggested a potential
pathway for paracellular transport by revealing that a negatively charged electrostatic surface exists in the C-terminal half
of ECS1, speciﬁcally the area between β3 and β4. As mutations
to residues in this area were known to reverse ion charge
selectivity (325), the structure explained how CLDNs may
govern ion selectivity in TJs. In addition, like IP39, the
mCLDN-15 packing within the lipid-ﬁlled crystal lattice suggested how CLDNs may polymerize. It was hypothesized that
lateral cis assembly of CLDN-based TJ strands in vivo resembles the linear arrangements found in crystallo between
certain symmetry mates. These packing arrangements would
be used as a basis for modeling of larger TJ polymer strands
and paracellular pores.
Throughout animal evolution, CLDNs and the paracellular
barrier have likely been subjected to many attempts at
disruption by pathogenic organisms seeking entry into
epithelial tissues. The spore-forming Gram-positive bacterium
Clostridium perfringens, for example, secretes a 35 kDa
enterotoxin (CpE) within the gastrointestinal tracts of humans
and domesticated animals that binds select CLDN subtypes
through recognition by its C-terminal domain (cCpE) (326).
The CLDN ECS2 alone was thought to be used for this
recognition (327, 328). However, structure determination of
CLDNs in complex with cCpE has revealed that cCpE binding
encompasses both ECSs (Fig. 9B). The cCpE has proven to be
an important tool for structural determination of CLDNs
because the toxin fragment adds a 15 kDa hydrophilic mass
to hydrophobic CLDN/detergent complexes, which allows for
formation of 3D crystals via traditional vapor diffusion
methods. The cCpE has enabled structural determination of
mCLDN-19 (329), human CLDN-4 (hCLDN-4) (330),
mCLDN-3 (331), and hCLDN-9 (332). To date, 89% of CLDN
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structures in the PDB are CLDN/cCpE complexes, highlighting cCpE’s value to CLDN structural biology.
In addition to enabling structural determination of several
CLDNs that were recalcitrant to crystallization alone, cCpEbound CLDN structures facilitated our understanding of
both fundamental and clinical aspects of TJ biology. CpE
binding to CLDNs is thought to disable both lateral and paracellular CLDN/CLDN interactions, inhibiting paracellular
pore and cell adhesion functions (329–332). Crystal structures
of CLDN/cCpE complexes explain how cCpE may disable both
types of CLDN/CLDN interactions (Fig. 9B). By encompassing
both ECS, cCpE can prevent CLDN/CLDN trans interactions
through steric shielding. The cCpE can also disable lateral
CLDN/CLDN interactions through cCpE-induced structural
perturbations of two extracellular helices shown to be involved
in cis assembly (329–332). In drug development and in the
clinic, the intermolecular interactions between cCpE and
CLDNs revealed by these structures are empowering efforts to
engineer cCpE for targeted destruction of CLDN-expressing
cancer cells (333–3335) and for improving drug delivery
through the blood–brain barrier (336, 337).
Structures of CLDNs have allowed for the modeling of the
other subtypes and their functional pore-forming assemblies
using in silico methods. The linear polymers of mCLDN-15
observed in LCP-grown crystals, packed in crystallographic
symmetry arrangements, form potential cis interactions using
adjacent ECS domains (321) (Fig. 9C). Building complexity
from this experimentally determined organization, a more
complex model was proposed where a row of linear polymers
could interact with a second row of linear polymers to arrange
in antiparallel double rows, with the ECS of neighboring
protomers creating β-barrel-like channels in paracellular space
(338) (Fig. 9D). Since, researchers have computationally
modeled an array of possibilities for how mCLDN-15 (339–
341) and other CLDNs (342–344) may assemble into large
complexes essential for paracellular barrier and pore function.
These predictions have provided testable models of CLDN
self-organization, pore structure and selectivity, and the cis
and/or trans interfaces that enable these assemblies and
functions. Although some models or portions of them have
been veriﬁed in vitro and/or in vivo using cross-linking,
mutagenesis, freeze-fracture EM, ﬂuorescence confocal microscopy, and FRET (338, 341, 342), an experimentally derived
structural basis for CLDN interactions and assemblies has yet
to be elucidated.
Recent progress in determining structures of CLDNs has
rapidly advanced our understanding of the interconnected
structural and functional biology’s of CLDNs and TJs and
the mechanisms by which a bacterial enterotoxin gains access to the mammalian gut. These advances are somewhat
limited by a lack of structural information for the multimolecular CLDN assemblies required to form TJ barriers
and pores and CLDN complexes with other TJ-constructing
proteins. The dynamic associations between soluble proteins
and MPs that properly assemble TJs under various physiological stimuli, which are thought to contain >40 proteins
(345), make for a potentially arduous yet exciting future for
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Figure 9. Claudin structures and models for assembly at tight junctions. A, 3D structure of mCLDN-15 (PDB 4P79). B, 3D structure of hCLDN-9 in
complex with cCpE (PDB 6OV2). C, the proposed linear arrangements of CLDNs as observed from the LCP crystal structure of mCLDN-15. D, structural model
of CLDN-based paracellular ion pores.

the ﬁeld. It is expected that structural biology will make
critical contributions to deconvolute and demystify how TJs
form and function at the subnanometer levels. Such discoveries will provide a rich source of information for
making new inroads in the design and development of
therapies to treat the plethora of TJ-linked diseases—like
cCpE-based therapeutics targeting cancer and neurological
disorders—effective, possibly, at the level of speciﬁc tissues,
cell clusters, or even individual TJs.
How do solutes cross the membrane?
One of the important categories of MPs are transporters for
solutes to cross the lipid membrane (346). These solutes either
become part of a metabolic cycle (e.g., glucose transporters)
and generate energy for the cell, or these solutes can act as
signaling molecules (e.g., Ca2+ ATPase that transfers Ca2+ ions)
to activate various biological processes (347). Active transporters, which utilize energy to transport substrates, are classiﬁed into primary and secondary active transporters based on
the energy source (348). Primary active transporters such as Ptype ATPases (e.g., Na+/K+-ATPases, Ca2+-ATPase, gastric
H+/K+-ATPase, fungal and plant H+-ATPases), V-type (vacuolar-ATPase), and ABC transporters depend on ATP hydrolysis to fuel the transport of solute across the hydrophobic lipid
membrane (349). Secondary transporters transport solutes
against their gradients by using the potential energy from

downhill electrochemical gradient of another solute (350). We
describe the impact of the PDB in the ﬁeld of one of the primary transporter classes, the ABC transporters (351). For
secondary active transporters, we focus on the major facilitator
superfamily (352).
ATP-binding cassette transporters
ABC transporters are one of the largest superfamilies of
MPs, ubiquitously present in all prokaryotes and eukaryotes
(353). They are involved in major physiological functions by
transporting diverse types of solutes including sugars, ions,
drugs, lipids, bile salts, amino acids, peptides, nucleotides
across membranes (354). Mutations are associated with a
number of diseases including cystic ﬁbrosis, Tangier’s disease,
Dubin–Johnson syndrome, and also account for multidrug
resistance in human cancers (355). ABC transporters are
classiﬁed as importers or exporters based on the direction of
substrate transport relative to the cytosol (356). According to
the new classiﬁcation, based on different structural folds, ABC
transporters are divided into type I to VII classes (357). These
transporters consist of two transmembrane domains (TMDs)
and two nucleotide-binding domains (NBDs). NBDs bind and
hydrolyze ATP to power the translocation of substrate across
the membrane through the transmembrane domains (358,
359). Some ABC importers also use accessory proteins to bind
the substrate with high afﬁnity and then transport it across the
J. Biol. Chem. (2021) 296 100557
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membrane (360). Structure entries since the 1990s demonstrate how the PDB remarkably impacted the ﬁeld of ABC
transporters (361).
Structures of ABC transporters not only provided insights
into the architecture of ABC transporters, but also contributed
toward understanding the alternating access mechanism in the
family. The Escherichia coli maltose transporter or MalFGK2, a
well-characterized model system of the ABC transporter superfamily (362, 363), imports maltose or maltodextrins with
lengths of up to 7 to 8 linked glucose units in coordination
with cell metabolism (364). Crystallographic snapshots of the
maltose transporter in different states demonstrate how it
utilizes an alternating access mechanism to transport maltose
from the periplasmic side to the cytosol using a periplasmic
maltose-binding protein (MBP, also named MalE) to feed the
transporter from the periplasm and ATP hydrolysis on the
cytoplasmic NBD domains (365). These studies revealed that
in the absence of MBP and nucleotide, the NBDs of maltose
transporter are well separated and do not hydrolyze ATP; a
state known as inward-open resting state (366). Binding of
maltose-binding protein charged with maltose and ATP
binding to the NBDs induces a conformational change that
brings the transporter into a pretranslocation semiopen state
in which the NBDs are not fully closed (Fig. 10A) (367). In the
next step, it undergoes a concerted motion in which substrate
is released into the intracellular cavity and NBDs dimerize or
close completely to initiate ATP hydrolysis; a state known as
the outward-open transition state (Fig. 10B) (368). ATP hydrolysis returns the maltose transporter to the resting state
through an intermediate posthydrolysis semiopen state and
releases the substrate to the intracellular side (Fig. 10, C and D)
(365).
In addition to elucidating the catalytic cycle of the maltose
transporter, structural biology of this transporter also
explained the biphasic behavior of its MBP-independent mutants such as MalG511 (366) and informed about substrate
speciﬁcity toward malto-oligosaccharides (369). MBP- independent mutants had high basal activity and showed an
interesting biphasic behavior in maltose transport assays, as
well as in ATPase assays in response to increasing equimolar
concentrations of MBP and maltose (370–372). Equimolar
concentrations of MBP and maltose had an activating effect at
low concentrations, but inhibitory effects at higher concentrations on these mutants (371, 372). These MBP-independent
mutants were hypothesized to resemble the transition state of
the maltose transporter, with lowered activation energy and
increased afﬁnity toward MBP (372, 373). The mutated residues in these mutants are located at regions near a periplasmic
gate involved in transition from the inward-open to the
outward-open state (366, 368, 374). Mutations in these regions
destabilize the maltose transporter in the resting state and shift
the equilibrium toward a transition state, which explains the
high basal activity of these mutants in the absence of MBP
(366, 372). Higher afﬁnity of MBP for the transition state
versus the resting state explained the biphasic behavior of these
mutants (372).

20 J. Biol. Chem. (2021) 296 100557

Along similar lines, TmrAB, a thermophilic bacterial homolog of the mammalian antigen-presenting ABC transporter
TAP1/TAP2 (375), was one of the ﬁrst ABC transporters with
pseudo-twofold symmetry, whose subnanometer resolution
structure was determined by Fab-assisted single particle cryoEM (376). In a remarkable tour de force, crystallographic
studies combined with cryo-EM studies determined the
conformational landscape of TmrAB in lipidic environment
during turnover conditions (375, 377). These studies demonstrated the inward-open and outward-open states as a part of
general alternate access mechanism and showed induced
conformational changes upon ATP binding and hydrolysis,
coupled with substrate movement across the membrane
(Fig. 10) (377). Advances in cryo-EM technology have enabled
deciphering the alternating access mechanism in individual
ABC transporters including the chloride transporter CFTR
(378–382), MRP1 (383–385), P-glycoprotein (386–388), and
BCRP (389–392).
The PDB facilitated further understanding of the catalytic
cycle of ABC transporters. As an example, the crystal structures (PDB 2R6G) of the maltose transporter (368) enabled
detailed dynamics studies using EPR (393, 394). The dynamics
of the maltose transporter determined by EPR complemented
the crystallographic structures representing the catalytic cycle
(395–397). Other ABC transporters including MsbA, LmrA,
ModBC2, BtuCD, P-glycoprotein, and TmrAB were also probed by EPR spectroscopy to understand similarities in catalytic
cycles and the differences that deﬁne unique features of each
ABC transporter (398).
Major facilitator superfamily (MFS) transporters
The MFS transporters are the largest family of secondary
transporters in which individual members translocate one of a
diverse range of particular substrates. The substrates include
sugars, ions, amino acids, and diverse metabolites (399, 400).
This superfamily is ubiquitous, found in all kingdoms of life,
and in all cells, and in humans many members are of direct
medical and pharmaceutical signiﬁcance.
The key aspect is that they alternately bind or release substrate on one side of the membrane and bind or release that
one molecule on the other side, termed alternate access. If the
cycle in Figure 11 is described as if a clock face, this is schematized in the 9 to 12 to 3 o’clock parts of Figure 11 (and vice
versa). This process can be proved using radioactive substrate
on one side of the membrane that appears on the other side of
the membrane, even against a concentration gradient of total
substrate in the opposite direction. It occurs between opposite
sides of a membrane-enclosed volume without any ion
gradient across the membrane. So-called “uniporters” do this
without coupling to any other ion or proton gradient and so
simply allow equilibration of substrate from one side to the
other to achieve equilibrium where both sides eventually reach
equal concentration. The glucose transporter GLUT1 falls into
this category. In biology the metabolism of glucose inside the
cell reduces cytoplasmic glucose inside and thus ensures that
GLUT1 actually leads to net import of glucose.
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Figure 10. The alternating access mechanism in ABC transporters deciphered by structural tools. For simplicity, the cycle direction describes an
exporter. Importers function in the opposite direction of the arrows. An ABC transporter in its inward-facing open resting state (PDB 3FH6 for MalFGK2, PDB
6RAN for TmrAB) binds to ATP in the presence (in the case of maltose transporter) or absence of substrate [A] to adopt an intermediate state (semiopen
pretranslocation state (PDB 3PV0) in the case of the maltose transporter, or an outward open occluded state in case of TmrAB (PDB 6RAI)). NBDs dimerize for
ATP hydrolysis in an outward-open transition state (PDB 2R6G for the maltose transporter, PDB 6RAH for TmrAB) [B]. ATP hydrolysis separates NBD domains,
and the ABC transporter adopts an inward open post hydrolysis state (semiopen state for maltose transporter (PDB 3PV0), inward-facing unlocked state for
TmrAB (PDB 6RAM)) [C], which resets the resting state [D]. To simplify the ﬁgure, the binding and release of substrate are shown only for the case of
exporters. Substrate is efﬂuxed outside at step [B] in the case of the exporters. In importers, the substrate is released inside at step [C and D]. Color coding:
MBP (MalE) = magenta, MalK chain A = red, MalK chain B = green, MalF = blue, MalG = yellow, ATP = cyan, maltose = brown. TmrA chain = pink, TmrB chain =
sky blue.

In the vast majority of MFS transporters, transport is obligately coupled to an electrochemical proton or Na+ gradient.
The gradient drives the transport of substrate against their
substrate concentration gradient, using the downhill free energy change of one process (i.e., the electrochemical ion
gradient) to drive the uphill process of the other (i.e., substrates). In transporters the movement of ion and substrate
may be in the same direction, termed symporters, or in the
opposite direction of the substrate transport, termed antiporters, and the processes are reversible, determined by the
relative concentration gradients of the driving ion and of the
substrate. In a closed system, they would reach a two-substrate
equilibrium. In cell biology though, the gradients of the driving
ions are continuously being generated by ATP-driven pumps
that then determine the direction of transporters that use
those gradients (352, 401). The PDB harbors 150 structure
entries of full-length or truncated MFS transporters bound to

substrates and small molecules determined by various
methods, most by X-ray crystallography with a few by cryoEM. These structures each outline different states around a
transport cycle (Fig. 11) that shows how small are the energy
barriers between different states around the Figure 11
clockface.
Mutations and misregulation of human MFS transporters
contribute to human diseases. GLUTs (glucose uniporter
family) are linked to various genetic and metabolic diseases.
Essential for maintaining glucose homeostasis their loss of
function or regulation can underlie type-2-diabetes (402).
GLUT1 is also overexpressed in many cancer types due to the
increased demand for glucose that plays a key role in tumor
growth (403–405). The substrates of GLUTs are not restricted
to glucose as some of the homologs transport urate or other
sugars broadening their contribution to human physiology. As
an example, GLUT9 transports urate and is implicated in
J. Biol. Chem. (2021) 296 100557
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Figure 11. Distinct conformations of major facilitator superfamily transporters. Representative structures for the distinct conformations in the substrate transport cycle are shown. The cytoplasmic side of the membrane is “down” and the outside of the cell upward in this ﬁgure. In the text the cycle is
described as if on a clock face. The structures of several MFS transporters are shown in their relative positions around the “clock.” A key point is that there is
no leakage in these transporters. The 9 to 12 to 3 and in reverse (clockface numbers) indicate exchange 1:1 of substrate. The 3 to 6 to 9 and back to 6 to 3
indicate the substrate-free transfer, which in the case of LacY is the critical part that then delivers the proton.

hyperuricemia and gout (406, 407). Other human MFS
transporters implicated in disease include human PEPT1 and
PHT1. They are involved in transport of small peptides, and
their misregulation can cause inﬂammatory bowel disease
(IBD) (408). Organic anion and cation transporters transport
large hydrophobic ions including neurotransmitters, hormones, various drugs and are associated with coronary heart
disease, IBD, prostate cancer, rheumatoid arthritis, and other
conditions (80, 409–411). Given the role of MFS transporters
in human health and disease, their structures are an important
driver for drug design.
The structures of MFS transporters shed light on their
fundamental mechanism (352, 400, 412). They have a single
central substrate-binding site and operate via an alternatingaccess mechanism that involves a rocker-switch type movement of the two halves of the protein (Fig. 11). The 12 TMs are
arranged into two six-helix bundle domains (TM1-6 and TM7-
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12) and the motion of the N- and C-terminal domains results
in alternating access, with the substrate-binding site as a pivot
point. Structures guide the notion of a shared MFS fold,
irrespective of their particular function as symporter,
uniporter, or antiporter, or substrate (Fig. 11). Salt-bridge
formation and breakage are involved in the conformational
changes of the protein during transport (352, 401). The
structures of MFS transporters suggest that there is more
to the mechanism of substrate translocation than just rigidbody movement of the two transmembrane halves. A more
compact arrangement of helices around the bound substrate
is found in some structures (413–415). Homology modeling,
MD simulations, and double electron–electron resonance
measurements suggest a similarly compact structure for the
substrate-bound lactose permease (LacY) (416–418). A
comprehensive analysis of MFS transporter structures by
Quistgaard et al. (401) revealed a possible gating mechanism
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for substrate transport. Therefore, the atomic resolution
structures of these transporters describe the unique aspects of
their functions and provide an overarching view of an underlying mechanism (Fig. 11).
Structural information helps classify MFS proteins into
subfamilies (352, 400) as some proteins with no detectable
sequence similarity may exhibit almost identical structural
arrangements. Mutants designed using biochemical and
biophysical analysis of MFS transporters help stabilize otherwise unachievable conformations within the transport cycle
(419, 420).
The lactose permease LacY of E. coli is one of the best
understood MFS transporters (421). It couples the proton
electrochemical gradient from outside to inside across the
plasma membrane of a bacterial cell to cotranslocation of a
galactopyranoside against its concentration gradient, into the
cell (422). The stability-conferring C154G mutant (in TM5)
binds substrate in the same manner as the WT LacY but with
negligible transport (423). This conformationally restricted
mutant led to the ﬁrst X-ray crystal structures of LacY,
perhaps because it was locked into position by the mutation
(424, 425). Later structures showed how LacY binds substrates
without this mutation (426) and related the difference in
binding of substrate versus water in the binding site to changes
in the environment of a nearby arrangement of titratable side
chains including E325, H322, K319, Y236, D240 that serve to
capture and release protons (412). Surprisingly the binding (or
unbinding) of substrate (the 9 through 12–3 position in
Fig. 11) did not change the protonation state of the protein as
measured by any release of protons upon binding substrate.
And the Kd for binding substrate remains unchanged up to pH
10.5 (427). So where does the coupled movement of the
driving H+ ion, that is, protonation and deprotonation, occur
to drive the process? Proton delivery occurs only if the protein
goes through alternate access without the substrate bound (6
o’clock in Fig. 11). The H+ ions get “squeezed out” from the
side that closes (3–6 or 9–6) to reach the occluded state (6 in
Fig. 11), but only when water rather than substrate ﬁlls the
substrate site (6 in Fig. 11). Effectively the active substratebinding site loses protons as water retunes the substrate site.
Once on the “other side” of the membrane, the site rebinds
protons from that “other side” (6–9, or 6–3 in Fig. 11) as the
pKa again quickly rises from around pKa of 5 in the wateroccluded state (6 in Fig. 11), to 10.5 when it opens to the
other side (Fig. 11). The process is driven by a sharp drop in
the pKa of the titratable substrate proximal region associated
with glutamate E325 when water is in the site, versus when
there is substrate in the site, i.e., the loss of a proton from that
conjugate site (428, 429). As the transporter closes, for
example, from the cytoplasmic side, if no substrate is bound,
the pKa of E325 system is lowered to release protons to the
closing side, and those protons are rapidly moved away via
water molecules.
In an effort to visualize the alternate access mechanism, two
conserved Gly-Gly pairs (G46/G370 and G159/G262) in LacY
were mutated to tryptophans to pry the alternate sides open.
The mutants modiﬁed the structure and were investigated

using transport and stopped-ﬂow binding measurements (430,
431). The double Trp mutant G46W/G262W locked the LacY
conformation into the outward (periplasmic)-open conformation and led to structures that deﬁned interactions in the
outward-facing state. A camelid-nanobody against the G46W/
G262W double mutant was screened against WT LacY and
selected for the locked conformation similar to the double
mutant (430, 432) beautifully validating these structures as
reﬂecting on pathway states of the “rocker switch” (419, 420)
(Fig. 11).
The sugar-transporting MFS transporter XylE (433), a
bacterial hGLUT1 ortholog, was one of the ﬁrst MFS transporters for which the structures of multiple conformations
were deciphered. XylE structures in complex with D-xylose
and D-glucose led to the structural understanding of its
speciﬁcity and provided the basis for subsequent mechanistic
understanding of hGLUT1 speciﬁcity (see How does
understanding of a glucose transporter selectivity and
conformational changes inform the development of GLUT1speciﬁc inhibitors?) (403, 434). A mixture of detergents and
substrate during crystallization led to an inward-open
conformation of XylE (435). Inspired by the double Trp
mutant of LacY, a similar mutant designed for XylE (G58W/
L315W) gave an outward-facing conformation (433).
Several general conclusions from MFS transporter structures ensue. Substrate binding, versus absence of substrate
binding, changes the environment of the titratable/ionbinding sites nearby the substrate so that the afﬁnities for
proton/ion are altered. In LacY, the “active site” pKa drops
(releases a proton(s)) only when LacY returns to the other
side empty of substrate. This mechanism beautifully explains
how an intrinsically reversible transport function couples
substrate delivery to one side (opening on that side), to
“squeezing out” the proton(s) on that same side, when
recycling empty of substrate to be available for another
substrate to be bound on the other side. There is no exact
stoichiometry of proton/ion to substrate, as determined by
the pKa values and may involve several H+ in this case, or
Na+ ions in eukaryotes. Thus the driving proton(s)/ion(s)
and substrate transport are coupled but differently in space
and in time (412).
Other superfamilies also work by alternate access. As an
example, several other Na+-driven transporters from different
gene families share a common fold with LeuT (see How do
drugs control our minds? Molecular insights for psychiatric
drugs) for the central core of ten TMs and seem to share a
common mechanism for coupling to Na+ even though they are
not conserved in sequence with LeuT itself. These include the
clinically important Na+-driven glucose transporters of the
SGLT family (436–440). Together these structures show how
their structures, rather than their sequences, identify common
mechanisms of transport.
How small viral transmembrane proteins could be a linchpin
of viral infection?
Now more than ever there is an increased interest in the
study of viral proteins. The focus has been rightfully placed on
J. Biol. Chem. (2021) 296 100557
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replicases, polymerases, and receptors that enable viruses to
pursue their dichotomic life cycle transitioning from a “lifeless”
state as a viral particle to a proliﬁc replicator when hijacking
the host-cell machinery. In the particular case of membraneenveloped viruses, the viral proteins essential to the ingress
of the virus into the host cells are MPs that are important drug
targets, as demonstrated with the spike protein from Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov2)
(441–443). However, there is a class of membrane-embedded
proteins termed VPs that are essential for virulence and
infectivity (444–446) and have proven to be a valuable but yet
elusive targets for therapies. VPs are small transmembrane
proteins (60–120 amino acids) that oligomerize into ion
channels capable of permeabilizing cell membranes (447).
They are classiﬁed into class I for single pass TMs and class II
for helix-turn-helix hairpin motifs (445, 447). Among the most
studied VPs are the M2 proteins from Inﬂuenza A (IA) (448–
455) and Inﬂuenza B (456, 457), VpU from HIV (458–467), the
Envelope protein from Coronaviridae (468–471), and the p7
protein from Hepatitis C virus (472–476) (Fig. 12). Although
all of the above have structures of either the full-length protein
or of the TM monomer deposited into the PDB, the oligomerization state and ion conductance mechanism of some of
these ion channels remain elusive given that the channel pore
lumen is often lined by hydrophobic amino acids (e.g., VpU
and Envelope protein SARS-Cov1 (467, 471)). Moreover, VPs
play diverse roles during the viral life cycle, modulating
different host cell functions by directly interacting with host
proteins (445, 458) or, as in the case of Inﬂuenza A VP M2,
effecting the membrane curvature associated with the maturation and release of viral particles (451).
The M2 proton channel of IA is a canonical VP with more
than 30 structures determined over the years informing many
biochemistry studies. This tetrameric ion channel is essential
for the IA infection. Upon acidiﬁcation of the endosome by the
cell machinery, M2 is activated to shuttle protons inside the
viral particle, triggering disassembly of the viral core protein
M1 and subsequent release of the ribonuclear protein complex
(477). The proton shuttling process from the virus exterior to
its interior by VP M2 is dependent on the protonation of
residue H37 (448, 450, 478–480). Another major player
involved in the proton conduction is W41, which, unlike other
MPs where the aromatic residues are located with polar
moieties oriented out from the membrane surface to act as
anchor, faces the interior of the pore lumen to function as the
channel’s primary gate (481).The S31N mutation in M2
(Fig. 12C), ﬁrst identiﬁed in 2006 and now prevalent in all
strains of the virus, has rendered M2 IA resistant to amantadine and rimantadine, antivirals widely used for the treatment
of ﬂu (482). The functional core of this channel is comprised of
a tetrameric helix bundle spanning the membrane and a juxtamembrane amphipathic helix that anchors the channel to the
membrane and is essential for the process of nascent viral
particle release from the host cell membrane (451) by inducing
negative curvature around the nascent virion budding neck
(483). The available structures of M2 IA have shown that
the mechanism by which amantadine and rimantadine
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block ion conductance is by physically plugging the ion
channel pore with their cage-like bulky adamantane chemical
moiety. The S31N mutation seems to prevent such inhibition
by placing a bulky Asn side chain in the pore entrance while
the V27A mutant accomplishes this by removing the bulky Val
side chain from the pore lumen that secures the inhibitor in
place (Fig. 12, B and C). Many structures of the S31N mutant
have been determined with the goal of understanding the
mechanism by which this mutation blocks the entrance of a
bulky ligand such as amantadine without affecting ion conduction (454, 484, 485). Recent studies, built on previous work
by screening adamantane-derived compounds as well as nonadamantane compounds (485–492) against the S31N mutant,
have identiﬁed inhibitors blocking the channel via the same
mechanism used by amantadine and rimantadine i.e.,
obstructing the channel pore (Fig. 12E).

Membrane protein structures instruct drug design and
protein engineering
More than 50% of approved drugs target GPCRs and ion
channels. Many drugs are metabolized by membraneassociated cytochrome P450s and/or exported by members
of the solute carrier family (SLC) or ABC transporters involved
in absorption, distribution, metabolism, and excretion of drugs
(493–496). The democratization of protein structures since the
establishment of the PDB has signiﬁcantly contributed to the
development of new therapies and the understanding of their
mode of actions. The availability of MP atomic coordinates
that can be accessed free of charge, viewed and manipulated on
any researcher’s computer opens endless possibilities such as i)
designing mutagenesis studies to understand the roles of
different residues in protein structure, function, and disease, ii)
guiding rational protein engineering and design efforts aimed
at improving the biophysical properties of protein targets to
facilitate drug discovery and iii) modeling of putative binding
sites. Structure-based drug development is one major area
where PDB continues to foster and beneﬁt the drug development process and ultimately leads to the more effective
treatments for patients.
Protein engineering allows use of proteins for new applications including many advances in structural biology.
Without the various puriﬁcation tags/fusions we now use
commonly, the PDB would still be limited to proteins from
natural sources (497). Protein engineering also had signiﬁcant
contributions to the structural determination of many MPs
themselves. The ﬂourishing ﬁeld of GPCR structural biology
would not have been possible without the use of fusion proteins (such as modiﬁed T4 lysozyme) as crystallization chaperones (498). With increased knowledge of MPs, they can be
used as powerful tools in many biochemical and biophysical
applications. However, they need to be modiﬁed and optimized
for applications under experimental conditions. The availability of structures of MPs is critical for optimizing properties
of interest.
In this section, these contributions of the PDB to understanding MPs in the context of therapy and the new ways of
understanding biological processes enabled by structure-based
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Figure 12. Viroporin structures. A, M2 PDB 2L0J (wild-type). Pore residues V27, S31, H37, and W41 highlighted in yellow. B, M2 PDB 2KWX (V27A mutation).
Pore residues A27, S31, H37, and W41 highlighted in yellow. C, M2 PDB 2N70 (S31N mutation). Pore residues V27, N31, H37, and W41 highlighted. D, M2
V27A mutant (PDB 6NV1) in the presence of the spiroadamantyl amine inhibitor. Drug in green and pore residues A27, S31, H37, and W41 in yellow. E, M2
S31N mutant (PDB 2LY0) in the presence of the drug M2WJ332. Drug in green and pore residues V27, N31, H37, and W41 in yellow. The mutants V27A and
S31N are both resistant to amantadine, the S31N mutant is the most common and now present in most Inﬂuenza A infections. The structures in panels C
and E differ by the length of the construct, the absence and presence of drug, and the environment in which the structures were solved. While the M2 S31N
structure in panel C was solved in liquid crystalline lipids environment, the structure in panel E was solved in a micellar environment. F, VpU TM pentameric
structure (PDB pi7) side and top view showing in yellow the residues V9, V13, I17, and V21 lining the channel pore. G, structure of SARS-Cov1 Envelope
protein TM and C-terminal domain (PDB 5X29) with pore lining residues N15, L18, A22, F26, V29, and I33 highlighted in yellow. H, Hepatitis C Virus p7 protein
structures PDB 2M6X (pentamer) and PDB 2MTS (monomer) ﬁtted to the cryo-EM density map (emd_1661) using ChimeraX.
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protein engineering of MPs will be explored through a few
illustrative examples.
How do structures of the membrane-bound cytochrome P450
enzymes inform the functional basis of monooxygenase
activities, contribute to understanding of drug–drug
interactions, and aid drug discovery?
Cytochrome P450 enzymes are monooxygenases with a
highly conserved and unique fold (499). They have evolved to
carry out speciﬁc metabolic reactions that help produce and
modify metabolites including sterols, some lipids, and vitamins, or they can act as more broadly speciﬁc activators or
detoxiﬁers of drugs. Despite this diversity of function and
substrate clientele, all cytochrome P450s have the ability to
generate, in a buried substrate speciﬁcity-conferring active site,
an Fe(IV)-oxo-porphyrin cation radical (compound 1) that
cleaves aliphatic carbon–hydrogen bonds by introducing an
oxygen and producing water (500). When the PDB Molecule of
the Month provided a succinct summary of current knowledge
of the structure, function, and mechanisms of cytochrome
P450s in 2006 (https://pdb101.rscb.org/motm/82), there were
about 13,000 DNA sequences for cytochrome P450s described
in databases and the PDB was dominated by crystal structures
of microbial cytochrome P450s. The cytochrome P450s of
higher eukaryotes had just begun to assume prominence in the
PDB with the lodging of crystal structures of the catalytic
domain of some membrane-bound drug metabolizing liver
enzymes, such as cytochrome 3A4 in complex with various
ligands (501). Now there are at least 600,000 cytochrome P450
DNA sequences and about 7000 NMR and crystal structures in
the PDB for these molecules, primarily due to genome
sequencing, the use of heterologous expression systems, and
the exploration of substrate and ligand binding by academia
and industry. This is enabling efforts to design more speciﬁc
ligands for pharmaceutical and agricultural purposes (502–
504), the use of mutagenesis and metal substitution to engineer new activities (505), and experiments that increase understanding of mechanistic features of cytochrome P450s.
Membrane-bound cytochrome P450s, which locate to the
endoplasmic reticulum or mitochondria of eukaryotic cells,
have catalytic domains with a comparable fold but were classiﬁed as signiﬁcantly structurally different from the soluble
P450s that occur in bacteria (506). This ﬁnding was based
primarily on the interaction of the heme ring C propionate
with the helices A–B loop in the case of the membrane-bound
enzymes and with helix C for the soluble enzymes. The
membrane-bound CYP51 enzymes provide an illustrative
exception to this generalization. Both soluble and membranebound enzymes in this phylogenetically ancient cytochrome
P450 family have their heme C propionate in an ionic interaction with a basic residue in helix C. A second factor used to
discriminate between soluble and membrane-bound cytochrome P450s was the increased length and more complex
disposition of the F–G helix region in the membrane-bound
cytochrome P450s.
The short region linking the F–G helices together with the
β1/β2 loop has considerable importance in membrane-bound
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CYP450s as they interact with the lipid bilayer surface and
contribute to the mouth of a substrate entry channel through
which hydrophobic substrates migrate from the membrane to
the active site. While structures of recombinant N-terminal
truncated eukaryotic cytochrome P450s, which present the
enzyme’s catalytic domain, are consistent with this relationship, it can be more directly inferred from biochemical labelling studies, computer simulations, and most importantly, the
crystal structures obtained for the full-length fungal CYP51
from Saccharomyces cerevisiae (Fig. 13, A and B) and the more
recent crystal structures of Candida glabrata and Candida
albicans CYP51s (507, 508). These molecules include an
N-terminal membrane associated α-helix and a TM that also
interfaces via hydrophobic and hydrogen-bonding interactions
with a portion of the surface of the catalytic domain. This
feature not only provides a membrane anchor but it also
orients the catalytic domain so substrates and inhibitors can
enter the substrate entry channel from the lipid bilayer. The
substrate entry channel and active site have been mapped in
numerous structures of S. cerevisiae CYP51 complexed
with ligands including a range of antifungal azole inhibitors
including posaconazole, itraconazole, ﬂuconazole, voriconazole, and VT-1161 plus several azole fungicides used in
agriculture (508–511). These structures identify interactions
between these ligands and the heme, speciﬁcity-conferring
amino acid residues lining the interior cavity of the protein,
and with key water molecules. Also visualized were interactions affected by species-speciﬁc substitutions that confer
inherent resistance to some classes of azole drugs (512) or
mutations that confer acquired resistance to some or all classes
of azole drugs (513, 514). The structural and phenotypic impacts of these substitutions and mutations are important
drivers of efforts to identify novel antifungals that will
circumvent these target-based azole-resistant phenotypes
(503).
A feature invoked for rational antifungal design is the similarity across phyla of CYP51 structures and the absence of
major structural rearrangements in complexes with various
inhibitory ligands or structural analogs (503, 515). However,
structures obtained for full-length and truncated CYP51s in
complex with the short-tailed tetrazole inhibitor VT-1161 and
the long-tailed triazole inhibitor posaconazole suggest that the
disposition of the mouth of the substrate entry channel
required for broad spectrum antifungal activity may be
compromised in truncated structures liganded with the shorttailed azole due to structure distorting intersubunit crystal
lattice interactions (509). Furthermore, poor substrate binding
for both truncated and full-length CYP51 molecules led to
conﬂicting proposals for substrate orientation. The likely
orientation of sterol substrates was recently clariﬁed using an
I105 F mutant of Trypanosoma cruzi CYP51 (516). The mutation converted a fungi-like eburicol-speciﬁc CYP51 to a
plant-like obtusifoliol-speciﬁc enzyme but with substrate occupancy increased to 85%. This allowed reliable visualization
of this substrate in the binding cavity formed by the B–C loop,
helix C, and helix I, with the obtusifoliol hydroxyl group oriented into the substrate access channel. Comparable
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Figure 13. Comparison of the full-length Saccharomyces cerevisiae CYP51 structure with structures of the human CYP51 catalytic domain. Helix B
and the B–C loop have been removed to visualize the interior of these molecules and their ligands. The catalytic domain of the full-length yeast CYP51
enzyme (A) in complex with posaconazole and the human catalytic domain in complex with two molecules of the inhibitor VFV (B) have essentially identical
folds, with their helix C K151 and K156 sidechains, respectively, making ionic interactions with the heme propionate. Ablation of the proton transfer
pathway in the human CYP51 D231/H314 mutant catalytic domain (C) gives substrate occupancy sufﬁcient to visualize lanosterol bound in an inactive but
catalytically competent state that demonstrates signiﬁcant conformational change in comparison with B. K156 no longer binds to the heme propionate—its
side chain projects above the enzyme’s proximal surface and the C-helix rotates slightly, uncoiling its center section, and facilitating binding of the cognate
NADPH-cytochrome P450 reductase in the vicinity of helix C. A slight reorientation of helix I caused by interaction with the hydrophobic tail of lanosterol
contributes to a signiﬁcant repositioning of the F-G helices. It changes in the ionic and hydrogen bond interaction between D298 and 299D, at the
N-terminal end of helix I, with basic residues (H257, K261, R272) and Y265 on helix G. This modiﬁes the position of helix G so that the F” helix almost
completely closes the entry to the substrate channel at the membrane surface. A positional change in the M487 side chain adjacent to helix F” is also
involved in substrate entry channel closure. This includes the formation of a water-mediated hydrogen bond network involving M378 and I379, located in a
substrate entry channel-lining internal loop, and the hydroxyl group of the bound lanosterol.

visualization of the substrate lanosterol was achieved with the
human CYP51 D231A H314A mutant (Fig. 13, B and C) that
has the salt bridge involved in proton delivery ablated (517).
Furthermore, with productive substrate binding by both the
protozoan and human enzyme, a signiﬁcant reorientation of
helix C occurred; the heme propionate-helix C ionic linkage
was lost and the freed basic side chain projected outward from
the enzyme surface.
Membrane-bound cytochrome P450s operate in a more
complex environment than the soluble enzymes and may
perform as molecular machines. They interact with a cognate
NADPH-cytochrome P450 reductase (CPR) that supplies pairs
of electrons, in some instances with cytochrome b5 and, when
taking part in metabolic pathways, with multiple downstream
enzymes that use the product of the cytochrome P450. For
example, an additional channel in the fungal CYP51 enzymes
bifurcates from the substrate entry channel (508). This channel
has been proposed to mediate product egress and interaction
with enzymes immediately downstream in the ergosterol
biosynthesis pathway, such as the Erg24 reductase and the
demethylating complex of Erg25, Erg26, and Erg27 that are
mounted on the Erg28 scaffold protein. Some of these
enzyme–enzyme interactions have been mapped in yeast systems using the split-ubiquitin system (518).
A recent study using docking techniques and molecular
dynamics has modeled possible interactions between
membrane-bound mammalian CPR and membrane-bound
CYP1A1 (449). The mimicking of complementary ionic, van
der Waals, and hydrophobic interactions between the CPR
FMN domain and the residues on the B, C, and L-helices, the

J-K loop and the loop structure in the proximal surface near
the CYP1A1 heme, plus the inclusion of a hydrogen bond
between the FMN phosphate group and the Q139 sidechain
in helix C, appeared to enable efﬁcient electron transfer to
the heme. Crystallographic and NMR analysis of the bacterial
cytochrome P450s, the camphor binding CYP101A, and
mycinamicin biosynthetic enzyme MycG, indicate the
movement of particular secondary structure elements during
substrate binding (450, 451). This ﬁnding has been validated
by site-directed mutagenesis experiments and used to suggest
a generally conserved mechanism for substrate binding and
recognition in the P450 superfamily. In CYP51s, accommodation of the substrate in a catalytically competent position is
now expected to drive reorientation of helix C and CPR
binding, close the substrate entrance channel, and activation
of the proton relay machinery via F-F”-G arm repositioning
and the His-acid salt-bridge opening required for the O–O
bond heterolysis (Fig. 13, B and C). This process has been
suggested to prepare the CYP51 catalytic machinery for the
three consecutive reaction cycles using compound 1 characteristic of this class of cytochrome P450. It occurs without
the substrate release after its ﬁrst and second monooxygenation reactions, distinguishing it from most other cytochrome P450s (447).
A major challenge in the P450 ﬁeld is understanding how
the membrane-spanning domains impact on the mechanistic
basis of eukaryotic cytochrome P450 function. For members of
the membrane-bound CYP51 family this will include determining how the protein subunits of this complex molecular
machine interact in an ordered fashion and how its sterol
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substrate is extracted from the membrane and reoriented in
order to present appropriately to a series of active sites. This is
now feasible through the incorporation of full-length eukaryotic cytochrome P450s, along with their cognate MP partners,
into membrane-mimicking environments such as nanodiscs,
together with the application of NMR and cryo-EM (452, 453).
Using structural knowledge of cytochrome P450 conformational states to generate new classes of antifungal agents not
susceptible to side effects caused by drug–drug interactions
with drug metabolizing cytochrome P450s in humans is an
exciting and much needed endeavor.
Can structural data provide a mechanistic understanding of
the loss-of-function mutations in the cystic ﬁbrosis
transmembrane-conductance regulator and guide the
development of compensatory therapies?
CF is a well-known genetic disease affecting approximately
70,000 people worldwide (519). It is caused by diverse mutations in the gene coding for the ABC transporter CFTR, which
leads to defective biosynthesis or misfolded or dysfunctional
CFTR protein. Lack of functional CFTR in epithelial tissues
disrupts salt homeostasis, leading to progressive lung disease,
exocrine pancreatic insufﬁciency, and intestinal abnormalities,
among many other symptoms. In the lung, CF is characterized
by excessive mucus accumulation contributing to obstructive
pulmonary disease, which is the main cause of morbidity and
mortality. Although still an incurable disease, life expectancy
for CF patients has steadily improved to around 40 years
thanks to better disease management and treatments that
resulted in part from a better understanding of CFTR (520–
522).
Since the discovery of the linkage between CF and mutations in the CFTR gene in 1989 (523–525), signiﬁcant progress
has been made in mechanistic understanding and therapy
design. CFTR is an ABC transporter that shares the two TMDs
and two NBDs that hydrolyze ATP characteristics of this superfamily (see How do drugs control our minds? Molecular
insights for psychiatric drugs), but includes an additional regulatory (R) domain and an N-terminal lasso motif (526). It is
the only known member of the ATP-gated ion channel family,
transporting chloride in an ATP-dependent and R domain
phosphorylation-dependent manner (361, 527, 528). More
than 350 CF-causing CFTR variants have been identiﬁed
(http://cftr2.org/). Two classes of CFTR-modulator therapies
have been designed to compensate for the malfunctioning
protein generated by these mutations. These include correctors such as lumacaftor, tezacaftor, and elexacaftor that assist
in CFTR protein folding and trafﬁcking to the cell surface,
while potentiators such as ivacaftor improve CFTR’s activity
(529, 530). Without structural information available, the main
discovery and optimization approaches involved intensive
high-throughput screening and structure–activity relationship
(SAR) campaigns (531, 532).
Recent structural efforts by Chen and colleagues are changing
that scenario, by solving CFTR structures in the dephosphorylated ATP-free form (379, 381), phosphorylated ATP-bound
form (380, 533), and phosphorylated ATP-bound form in
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complex with potentiators (534). Many CF-causing mutations
could be mapped into these structures, and their negative effect
rationalized as affecting the pore construction, protein folding,
the ATPase site, or the NBD/TMD interface. The cryo-EM
structure of the phosphorylated ATP-bound human CFTR
(hCFTR) E1371Q mutant in complex with potentiators ivacaftor
(an FDA-approved drug developed by Vertex Pharmaceuticals)
and GLPG1837 (an investigational drug developed by Galapagos) shed light on how these molecules improve hCFTR
activity in CF patients (Fig. 14A) (534). Ivacaftor-bound
E1371Q, phosphorylated and ATP-bound, exhibits the same
conformation as the ivacaftor-free structure. Interestingly, ivacaftor binds CFTR at the protein–lipid interface in a clef formed
by TM helices 4, 5 and 8. As shown in previous structures, TM8
rotates upon phosphorylation and ATP binding, and ivacaftor
appears to stabilize this rotation. Ivacaftor might thus function
by favoring the open conformation of the pore. Residues L233,
F236. Y304, F305, S308, F312, F931, and R933 are identiﬁed as
key in the CFTR–ivacaftor interaction (Fig. 14B) and correlate
with previously published SAR studies that led to ivacaftor’s
development (531). The elucidation of GLPG1837-bound
E1371Q, phosphorylated and ATP-bound structure (Fig. 14C)
showed that although chemically dissimilar to ivacaftor, its
interaction with CFTR largely overlaps ivacaftor’s binding site.
Both ivacaftor and GLPG1837 were discovered by extensive
high-throughput screening, followed by further optimizations
through SAR (531, 532). The availability of these potentiatorbound structures, and future corrector-bound structures,
could represent a new avenue for the development of more
efﬁcient CF treatments.
Other structures of ABC transporters have contributed to
therapy. It is noteworthy that the breast cancer resistance
protein (BCRP or ABCG2) and P-glycoprotein efﬂux a number
of drugs, affecting their pharmacokinetics and bioavailability
and mediate multidrug resistance. Their structures were
elucidated in different conformations, in the presence and
absence of drugs, paving the way for the development of a
newer generation of drugs that can inhibit or evade multidrug
resistance associated with these transporters (386–392).
How does understanding of a glucose transporter selectivity
and conformational changes inform the development of
GLUT1-speciﬁc inhibitors?
Glucose is an essential source of energy used by tumor cells
to produce ATP, maintain the reduction–oxidation balance,
and generate biomass (535). Glucose transporter GLUT1 is
overexpressed in many types of cancers, including the brain,
colon, kidney, lung, ovary, and prostate, and represents a
promising target for therapy (536). However, there are 14
GLUT transporters in humans, and due to their high sequence
homology, many GLUT inhibitors lack isoform speciﬁcity
(537–541). The development of GLUT1-speciﬁc inhibitors
would thus beneﬁt from the understanding of its atomic
structure and the identiﬁcation of key residues that could be
targeted for selective inhibition.
Initial structural and mechanistic understanding of glucose
transport by GLUTs was provided by studies focusing on
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Figure 14. Structural understanding of CFTR function and therapeutic targeting. A, structure of the phosphorylated, ATP-bound hCFTR in complex with
ivacaftor (PDB 6O2P). Ribbon representation, with TMD1 and NBD1 colored in cyan, TMD2 and NBD2 in green. The approximate location of the lipid bilayer is
shown in gray. Ivacaftor is shown in magenta, in stick representation. ATP-Mg2+ molecules are shown in sphere representation (carbon in green, nitrogen in
blue, oxygen in red, Mg2+ in yellow). B, close-up image of main interactions between hCFTR and Ivacaftor (PDB 6O2P). A selected number of interacting
residues are shown in stick representation, carbons are colored in cyan (TMD1) or green (TMD2), nitrogen is blue, oxygen is red. C, close-up image of main
interactions between hCFTR and GLPG1837 (PDB 6O1V). Main interacting residues are shown in stick representation, carbons are colored in cyan (TMD1) or
green (TMD2), nitrogen is blue, oxygen is red, sulfur is yellow.

bacterial homologs (see How do drugs control our minds?
Molecular insights for psychiatric drugs). The ﬁrst human
GLUT1 (hGLUT1) structure was determined by Deng et al.
(403). It contained mutations N45T, which removed a glycosylation site, and E329Q, which blocked the transporter in an
inward-facing conformation. Interestingly, a molecule of βnonyl glucoside, the detergent used during puriﬁcation, was
present in the inward-open cavity, with the D-glucopyranoside
headgroup bound to the C-terminal domain near the center of
the membrane, overlapping with the glucose-binding site
observed in the bacterial homolog XylE structure in complex
with glucose (434). The structure provided a molecular basis
for interpreting mutations linked to disease. These inactivating
variants could be clustered within the substrate-binding site, at
the interface between the TMDs and the intracellular helix
(ICH) domain, and throughout the lining of the transport path.
Kapoor et al. (405) reported three structures of wild-type
hGLUT1 cocrystallized with drug leads, the cell-permeable
mycotoxin cytochalasin B, and two new inhibitors identiﬁed
by high-throughput screening, GLUT-i1 and GLUT-i2.
Despite different chemical structures, the three inhibitors
bind to the proposed glucose-binding site in the central cavity,
with hGLUT1 residues S80, T137, Q282, W388, N411, and
W412 interacting with all three ligands (Fig. 15). The IC50
values of cytochalasin B, GLUT-i1, and GLUT-i2 bound to
GLUT2-4 highlighted differences in speciﬁcity. When
combining the crystal structure of GLUT1 bound to these
compounds with the corresponding structure-derived molecular models for hGLUT2-4 bound to them, comparison of
interacting residues and potential differences could inform the
development of future, more-speciﬁc compounds.
The structural information generated represents a practical basis for the development of more speciﬁc GLUT1
inhibitors. While the previous development of GLUT
inhibitors was based on high-throughput screening and
SAR-based optimizations (536), activity-based and in silico

screening campaigns to identify speciﬁc GLUT inhibitors
relying on structural information are starting to bear fruit
(542–544). The structure of the main sugar transporter
PfHT1 from the malaria parasite was determined recently by
two groups (545, 546). In one of the studies, the highresolution structure was used to allow rational design of
more potent and selective inhibitors of PfHT1 that could be
used to treat malaria. With an increasing number of GLUT
structures being determined, one can expect a new generation of potent and speciﬁc GLUT inhibitors developed with
similar structural-based strategies to treat diverse diseases.
Public access of structures through PDB is no doubt a pillar
for such endeavors.
How do drugs control our minds? Molecular insights for
psychiatric drugs
The majority of signal transduction events in our brain are
mediated by small molecules known as neurotransmitters.
Neurotransmitters in the cytosol must be packaged into synaptic vesicles by vesicular neurotransmitter transporters before
they can be released from the presynaptic axon by exocytosis
upon action potential stimulation (547–549). The released
neurotransmitter then elicits their effects by binding to two
kinds of membrane receptors on the postsynaptic dendrite:
ionotropic ligand-gated ion channels (LGICs) for fast response
or metabotropic GPCRs for slow effects (550, 551). To ensure
proper synaptic transmission, it is equally important to
terminate the signal promptly by rapid removal of neurotransmitters from the synapses after their release. This is often
achieved by high-afﬁnity neurotransmitter transporters located
on the plasma membrane of presynaptic termini and in the
surrounding glial cells (552, 553) or by diffusion and hydrolysis
of the neurotransmitter (554).
Use of chemical substances to change mood and behavior
dates back several thousands of years with well-known examples including coca (cocaine), coffee (caffeine), alcohol, and
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Figure 15. Structural understanding of the function and transport inhibition of human GLUTs. A, structure of hGLUT1 bound to cytochalasin B (PDB
5EQI). hGLUT1 is in cartoon representation, with its N-terminal domain colored green, ICH orange, and the C-terminal domain cyan. Cytochalasin B is shown
in stick representation, colored in magenta. The approximate location of the lipid bilayer is shown in gray. B, close-up image of main interactions between
hGLUT1 and cytochalasin B (PDB 5EQI). Main hGLUT1 interacting residues and ligand are shown in stick representation, carbons are colored in green
(N-terminal domain), cyan (C-terminal), or magenta (ligand), nitrogen is blue, oxygen is red. Residue labels in bold highlight common interacting residues
with cytochalasin B, GLUT1-i1, and GLUT-i2. C, close-up image of main interactions between hGLUT1 and GLUT1-i1 (PDB 5EQG). Same labeling and coloring
scheme as in (B), with the addition of ﬂuorine (orange).

marijuana (cannabis). Modern research on these compounds
as psychiatric drugs began after World War II with advances in
chemical synthesis and animal testing. In parallel, critical advancements in neuroscience and molecular biology allowed
the identiﬁcation of the target proteins for these drugs and
understanding of their effects. It is not a surprise that most of
these compounds target MPs located at the synapse. In fact,
almost all MPs that bind neurotransmitters are intensively
studied as drug targets. Particularly, LGICs and neurotransmitter sodium symporters (NSSs) are amongst the top ten
families of all FDA-approved drugs, accounting for 7.9% and
2.7% respectively (555). On the other hand, the recent
epidemic of drug abuse spotlights a lack of advancement in
this area. In fact, most currently used psychiatric drugs were
developed in the mid-to-late 20th century. Their use/misuse is
associated with side effects, and they are criticized for
contributing to addiction. This highlights the need to develop
more speciﬁc drugs with less side effects and that are less likely
to be addictive. The availability of structures of these MPs in
complex with their endogenous ligands and/or drugs in the
PDB is the basis for such efforts. Research on psychiatric drugs
over the past 50 years is a good example of how structures of
MPs have helped to elucidate the mechanisms of action of
drugs.
LGICs located on the postsynaptic cells are the major effectors of neurotransmitters. They underlie the rapid phasic
synaptic transmission. The receptor for the major inhibitory
neurotransmitter GABA is a Cl− channel that hyperpolarizes
the postsynaptic cell and reduces the ﬁring probability of the
receptor neuron when activated (550). As a result, ligands of
GABAAR are highly sought-after as psychiatric drugs.
GABAAR belongs to the Cys-loop receptor family together
with the receptors for glycine and acetylcholine, all of which
have had their structure and pharmacology intensively investigated (41, 75, 550, 556–569). The structure of the Cys-loop
receptors forms a pentameric ion channel made of ﬁve
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similar but nonidentical subunits (Fig. 16, A and B). Each
heteropentameric channel is typically assembled with 2 α, 2 β
and 1 γ (or δ) subunits. There are 19 genes encoding for the α,
β, and γ subunits of the GABAAR in humans that are differentially expressed in different regions of the brain. The assembly of different subunits of GABAAR results in complex
heterogeneity in their structures and is the major determinant
of their differing functions in distinct regions of the brain and
their complex pharmacological proﬁle (570, 571). Several
recent structures of GABAAR in complex with various ligands
have provided unprecedented insight into the molecular
mechanism of some commonly used psychiatric drugs (556,
564, 566–568). For instance, both Valium (benzodiazepine)
and Xanax (alprazolam) bind to GABAAR at the benzodiazepine site between subunit α and γ on the extracellular ligandbinding domain (Fig. 16C) while the endogenous ligand GABA
as well as bicuculline binds at the interface between the α and
β subunits (Fig. 16D). Structures of GABAAR revealed that
Benzodiazepines potentiate the effect of GABA by improving
the connectivity between subunits allosterically while bicuculline competes with GABA at the same binding site to
prevent the channel from opening. On the other hand, Flumazenil, which is used clinically to treat benzodiazepine
overdose, competes with benzodiazepines at the same binding
site (Fig. 16C). The neurotoxin picrotoxin, which is used as
stimulant and convulsant, directly blocks the ion-conducting
pore (Fig. 16H). The structures also revealed a previously
unknown second binding site for the benzodiazepine at the
transmembrane region (Fig. 16E) as well as several binding
sites for anesthesia agents in the transmembrane region
(Fig. 16, F and G). This information highlights new possibilities
for drug interaction. The structures of GABAAR bound with
substrate and drug ligands are major step forward toward
better psychiatric drugs.
Another way of modulating synaptic transmission is by
regulating the concentration of neurotransmitters at the
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Figure 16. Structural basis of psychiatric drugs targeting GABAAR. A and B, overall structure of GABAAR with one representative ligand at each
distinctive binding site shown in sphere representation. C–H, composite structure of GABAAR with ligands binding at different sites (PDB 6HUO, 6HUP, 6HUK,
6HUJ, 6HUG, 6I53, 6D6U, 6X3X, 6X3U, 6X3Z, 6X40, 6X3S, 6X3W, 6X3V, 6X3T).

synaptic cleft. In fact, the most popular marketed antidepressants, such as Prozac (Fluoxetine), Zoloft (Sertraline), Celexa
(Citalopram), all use this strategy. The selective serotonin reuptake inhibitors (SSRIs) are a group of drugs targeting serotonin transporters on the plasma membrane of the presynaptic
neurons (572). As deﬁciency of serotonin and dopamine (DA)
is implicated in depressive disorders, increasing their availability at the synapse through blocking their reuptake is
commonly used to treat depression. The dopamine pathway
has been targeted for the treatment of depression since the
early 1950s with the use of monoamine oxidase inhibitors
(MAOIs) and tricyclic antidepressants (TCAs) (572). However,
they have undesirable adverse effects and a high potential for
toxicity. With the identiﬁcation and cloning of the transporters
for serotonin (SERT), dopamine (DAT), and noradrenaline
(NET), SSRIs are designed to speciﬁcally inhibit SERT but with
minimal inhibition of NET, which was the source of side effect
of antihistamine used earlier. Major chemical synthesis efforts
together with in vitro/in vivo screening and testing from major
pharmaceutical companies successfully identiﬁed several SSRIs

that were much more selective and with less adverse effects
compared with TCAs. Since 1987, an increasing number of
SSRIs have been marketed and used to treat depression till the
current day and hailed as a great success for rational drug
design. However, the secret of success remains somewhat
mysterious, as no one really understood how these drugs were
able to interact selectively with SERT, but not the very similar
DAT and NET, at the molecular level. The availability of
structures of these transporters in complex with substrates and
drug ligands is starting to provide the answer.
SERT, DAT, NET all belongs to the SLC6 family of NSSs.
They are high-afﬁnity transporters for biogenic amines
(dopamine, serotonin, and noradrenaline) driven by the sodium gradient across the plasma membrane. Following intense
efforts, the structure of a bacterial homolog of SLC6 family
transporters, a leucine transporter from Aquifex aeolicus,
LeuT, was ﬁrst determined in 2005 (60). LeuT revealed the
“5 + 5” inverted repeat structural fold for the ﬁrst time
(Fig. 17A), which is highly conserved throughout evolution.
The structure of LeuT also identiﬁed two highly conserved
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Figure 17. Structural basis of antidepressants targeting SLC6 family NSSs. A, structure of LeuT (PDB 2A65) deﬁnes the common structure of the SLC6
family transporters. LeuT is composed of 12 TMs. TM1-10 forms the signature “5 + 5” inverted repeat with TM1-5 (light blue) and TM6-10 (pink) forming the
core domain repeating each other with a pseudo twofold symmetry along the substrate binding site. TM11 and TM 12 (yellow) are located at the peripheral
of the core domain. The substrate leucine is shown as cyan sphere while the two sodiums are shown in purple. B, ligand-binding site structure of dDAT in
complex with substrate dopamine as well as other psychostimulants (PDB 4M48, 4XP6, 4XP9, 4XP1, 4XP4, 4XP5). C, ligand-binding site structure of hSERT in
complex with common antidepressants (PDB 6AWO, 5I73, 5I6X, 6AWP). Na+ is shown in purple while Cl− is shown in green.

Na+-binding sites and elucidated the substrate transport
mechanism. More importantly, the structure of LeuT provided
a blueprint for understanding the substrate speciﬁcity of SLC6
transporters, which are central for the selectivity and efﬁcacy
of the SSRI antidepressants. In one approach, the substratebinding site of LeuT, which binds to leucine naturally, was
engineered to harbor residues that would bind to the biogenic
amines. Structures of the chimeric transporter LeuBAT in
complex with four classes of antidepressants (SSRIs, serotonin
norepinephrine reuptake inhibitor, TCA, and Mazindol) were
determined, and this provided the ﬁrst glimpses of how these
drugs interact with NSS transporters (573). The structures of
Drosophila DAT in complex with endogenous substrate
dopamine, as well as cocaine, amphetamines, and TCA antidepressants were subsequently determined in 2013 and 2015
(574, 575) (Fig. 17B). Finally, the structure of the human SERT
was determined recently in complex with several TCAs and
SSRIs by both X-ray crystallography and cryo-EM (576–579)
(Fig. 17C). These structures clearly illustrate that the majority
of antidepressants targeting NSSs function through competing
with the endogenous substrates at the central binding site.
However, a second allosteric binding site at the entrance to the
central binding site was observed in several structures, suggesting additional factors that may inﬂuence the selectivity.
These structures also further elucidated the transport mechanism of eukaryotic NSSs, which are also regulated by Cl−, K+,
and membrane lipids. These structures provide a much better
understanding of how antidepressants act upon NSSs. Their
availability in the PDB provides an invaluable resource for
structure-based drug discovery and development that will
surely lead to better antidepressants.
How can membrane proteins be engineered to advance
biological discovery?
Neuroscientists have dreamed for decades of controlling
speciﬁc groups of neurons in free-living animals to interrogate

32 J. Biol. Chem. (2021) 296 100557

functions of neuronal circuits. Optogenetics enables exactly
that, with the help of a family of light-sensitive algal membrane
channels called Channelrhodopsins (ChRs). Protein engineering is enabling ﬁne-tuning of the properties of ChRs to allow
an ever-growing range of applications (https://web.stanford.
edu/group/dlab/optogenetics/index.html). This topic has
been reviewed previously by the founders of the ﬁeld, Deisseroth and Hegemann (580, 581). Here we brieﬂy illustrate
the contribution of PDB in the exciting endeavor to understand the human brain and behavior.
Although naturally existing ChRs have been used in pioneering optogenetic studies since 2005 (582), it was really
structure-based protein engineering that fueled the tremendous developments that allowed it to become a powerful and
versatile tool for neuroscience. ChRs are seven TM integral
MPs that use retinal as chromophore and function as cation
channels. Fortunately, the structure of their remote cousin,
bacteriorhodopsin, was among the ﬁrst MPs to be determined.
Bacteriorhodopsin and ChRs share the same 7-TM structure
fold with a similar binding site for the chromophore retinal
(Fig. 18, A and B). With hundreds of structures already
determined and detailed biophysical characterization available,
bacteriorhodopsin allowed models of ChRs to be built. These
helped in optimizing the optical properties and resulted in
several useful modiﬁed ChRs. For instance, the ChETA variant
was obtained by mutating E123 of ChR2 and allows fast-ﬁring
at 200 Hz or more (583). Modiﬁcation of TM3-TM4 interaction at the CD pair (C128-D156 in ChR2) resulted in the stepfunction opsins, SFOs, which enable bistable excitation
photon-spike logic (584–586). A diverse family of red-shifted
C1V1 ChRs were created by modiﬁcation of the ChR from
alga Volvox carteri (587–590). The crystal structure of a
chimera between ChR1 and ChR2, C1C2, determined in 2012
(591, 592) (Fig. 18B) further clariﬁed the location and structure
of the light-activated pore and made even more designer ChRs
possible. In particular, the structure revealed that the internal
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Figure 18. Protein engineering applications based on membrane proteins. A, structure of the bacteriorhodopsin (PDB 1AP9). B, structure of the C1C2
ChR (PDB 3UG9). In both (A) and (B), the retinal is shown as magenta sticks while residues forming the retinal binding site are shown as dark green sticks.
Residues along the ion-conducting pathway of ChRs are shown as orange sticks on the C1C2 structure in (B). Refer to Ref. (580) for more details.
C, electrostatics of the vestibule of C1C2 ChR. D, electrostatics of the vestibule of the designed anion channel iC++ (PDB 6CSN). E, design of the dLight
dopamine sensor (used with permission (602)).

vestibules of the cation conducting ChRs are lined with
negatively charged residues (Fig. 18C). Guided by the structure, mutagenesis of residues lining the vestibule reversed the
charge. This resulted in a highly Cl− selective ChRs (iC++)
(Fig. 18D) (593, 594) now widely used to elicit inhibitory
stimulation. Optogenetic is a fast-growing ﬁeld with applications requiring ChRs with a wide range of properties. As
illustrated here, the availability of the structures of the natural
and designed ChRs will continue to be a major driving force
for further advancements.
Genetically encoded sensors are widely used in biophysical
and cell biological investigations. It is not an overstatement
that ﬂuorescent proteins, such as the green ﬂuorescent proteins (GFP), enabled modern cell biology. Structure-guided
protein engineering that combines a ﬂuorescent protein
with another functional group has allowed various physiological processes to be monitored and investigated by ﬂuorescent methods in cell cultures and in animals. For instance,
the calcium sensor GCaMP was created by fusing of the GFP
with the calcium-binding protein calmodulin and an M13
peptide from myosin light chain kinase (595). Similarly, the
glutamate sensor iGluSnFR (intensity-based glutamatesensing ﬂuorescent reporter) was obtained by fusion of a
circularly permutated enhanced green ﬂuorescent protein
(cpEGFP) with a bacterial glutamate-binding protein (596,
597). Both GCaMP and iGluSnFR, as well as their variants,
are now widely used to study calcium signaling and glutamate neurotransmission. Due to the difﬁculties with MPs,

applications of genetically encoded MPs lagged behind those
of soluble proteins by a few decades. In recent years, however, with the exponential growth in the available structures
of MPs, applications of MPs as genetically encoded sensors
are gradually emerging.
Dopamine is an important neuromodulator of complicated
behaviors such as motivation, rewards, learning, and motor
control. There is thus a large demand for monitoring its
concentration in cells and in animals. However, unlike other
neurotransmitters, such as glutamate and GABA, dopamine
exclusively activates the metabotropic GPCRs. Without eliciting any direct electrical response, it is hard to monitor
dopamine by using electrophysiological techniques. Fortunately, the structures of three out of the four dopamine receptors (all members of the GPCR family) were determined
recently (598–600). The structures allowed two groups to
independently design ﬂuorescence sensors for dopamine based
on the dopamine receptors. Tan’s group designed several
dopamine ﬂuorescent sensors (dLight) by replacing the third
intracellular loop of human dopamine receptor D1, D2, and
D4 with the cpGFP module from the GCaMP6 (Fig. 18E). The
ﬁrst generation of dLight sensors have already been successfully used in cell cultures, slice preparations, and free-moving
mice. Similarly, Li’s group obtained the GPCR-activationbased dopamine sensors, GRABDA, by inserting the cpEGFP
into the intracellular loop 3 of the D2 dopamine receptor. This
construct enabled successful measurement of dopamine concentration in mice, ﬁshes, and ﬂies (601).
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With an increasing number of MP structures determined in
recent years, there is no doubt that more applications in
addition to those illustrated here will emerge. The free availability of structures to all protein engineers is critical knowledge that will allow this ﬁeld to thrive.

Future perspective
The Coronavirus Disease 2019 (COVID-19) pandemic
dominated world attention in 2020 (603, 604). The main
routes to eliminate this infectious disease currently focus on
two MPs: the viral spike protein (605, 606), and the
membrane-bound form of the Angiotensin Converting
Enzyme 2 (ACE2) on the lung epithelial cell (607). Vaccines
target the viral spike protein to activate an immune response.
Peptides attempt to target the ACE2 site without altering its
essential human function (608). The primary preventative
focus now includes mRNA-based and virus-based vaccines
that encode the Spike protein and other membrane proteins
that then excite the immune response ahead of encounter with
the virus. Vaccines encoding the Spike protein mRNA use
lipid-based micelles or viral vectors for entry into human cells.
The lessons learned in 2020 provide a template to combat
pandemics. Can we now develop general strategies for
COVID-19, and for inevitable future infectious agents, by
preventing the early-stage interactions required for pathogenesis? Prevention of the spike protein–ACE2 interaction, a
feature that was swiftly determined at the structural level, has
the potential to provide stop-gap therapy until a much-needed
cure can be discovered and implemented. For example,
monoclonal antibodies or VH domains could block critical
entry interactions. Structural science has produced several
exciting templates for this important direction.
The newest exciting tool in this endeavor is a protein folding
program, AlphaFold 2, created by Google’s DeepMind group
and showing revolutionary accuracy in predicting protein
structure directly from sequence in a blinded competition (the
14th Critical Assessment of Structural Prediction competition,
CASP14) (609). The program, utilizing “Artiﬁcial Intelligence”
trained on the high-quality structures available in the PDB,
follows closely on the heels of the cryo-EM revolution and
heralds a future with rapid access to more precise MP structures, potentially solving the bottleneck in structure-based
drug design. The structures of MPs are, so far, less accurately predicted, but the Tidow group reports that after 2 years
of unsuccessful work on solving the crystal structure of the MP
FoxB, they succeeded using DeepMind’s prediction in a few
hours by molecular replacement (610). Undoubtedly the program will become even more precise and valuable for MPs as
new structures are solved by the powerful technological advances discussed above.
Traditionally, many long-standing and emerging diseases
have been accorded low priority by the pharmaceutical industry due to the limited commercial value of potential
therapies. We might imagine that MP-based strategies that
target key ﬁrst steps in the pathogenesis of such diseases
could become a focus of the World Health Organization.
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Given the experience of 2020, there should be good reason to
hope that scientiﬁc funding organizations will have the
insight and preparedness to accelerate funding for approaches that investigate the key membrane-associated
mechanisms deﬁning the pathogenicity of each newly found
infectious agent, be it viral or microbial, as soon as its danger
is recognized. There are some critical limitations in readily
obtaining the structures of MPs. These include “pulling out”
the full complement of molecular machines from their wildtype living organism in action, expressing functional MP at
the levels required for structural studies, addressing the underrepresentation of the full-length structures of lowmembrane pass proteins, and the ongoing challenge of
obtaining relevant structures that reveal the key conformational changes during reaction or transport cycles. Advances
in X-ray laser-based structure determination for small crystals and cryo-EM already provide valuable technological additions to the current armamentarium of biologists interested
in MP structure and function (611, 612).
Few proteins work alone! Proteomic mapping has
expanded the prospects for understanding MP function in
greater detail, particularly in contexts in which complexes of
proteins come together to regulate and coordinate multiple
regulated functions. Mass spectrometry is key to identifying
the proteins that associate with each other over time and
circumstance (603, 604). One very exciting approach is to
ask such questions in a normal cell without the overexpression of proteins. This can be achieved by genetically
adding an afﬁnity tag then “pulling it down” with the proteins actively associated with it (613). Cryo-EM is well suited
to determining structures of larger complexes of proteins,
including those at low endogenous levels (Most extreme
translocation: Effector protein and virulence factor secretion
in pathogens). This process will dramatically expand horizons over coming years, with afﬁnity puriﬁcation of large
complexes of proteins revealing the mechanisms of such
assemblies. Furthermore, cryo-EM can visualize multiple
structural states at different stages in their reaction cycles
and even model multiple and anharmonically coupled states.
In principle the distribution of these states provides snapshots of the system in action and can be used to estimate
the free energy difference between states of similar probability. Such approaches promise numerous new structures
and insights that will close the gap between the functions of
proteins acting as individuals and their roles within the
complexes in which they function, in different states across
time within a normal cellular environment.
Determining the relationships between structure and function of MPs relies on communication, deposition, and
dissemination of structural coordinates. Here we highlight a
small selection of discoveries from a plethora that have
stemmed from these endeavors. We provide a glimpse into
how MP structure determination has been enabled by parallel
technological developments, how these structures inform
about biological function and mechanism, and how MP
structures supply foundations for diverse ﬁelds including
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protein engineering, the simulation, and further exploration of
biological functions and processes associated with membranes,
as well as drug discovery and design. The PDB provides an
ever-growing treasury of MP structures—an everlasting,
powerful, and enriching product of global efforts.
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